The Lynx Group
Association for Value-Based Care
Association for Value-Based Cancer Care Summit

October 14-16, 2020 | New York Athletic Club, New York, NY

Download the 2019 AVBCC Summit App!

    • James Almas, MD
    • VP and National Medical Director for Clinical Effectiveness
    • LabCorp
    • Peter Bach, MD
    • Director, Center for Health Policy and Outcomes
    • Memorial Sloan Kettering Cancer Center
    • Kendra Barber, MHA, RN, OCN
    • Division Director, Navigation, Cancer Services
    • Sarah Cannon Cancer Institute
    • Sarah Beadling
    • Director, Operational Innovation
    • Cancer Treatment Centers of America
    • Al Benson III, MD, FACP, FASCO
    • Professor of Medicine, Robert H. Lurie Cancer Center
    • Northwestern University; Past Chair, National Comprehensive Cancer Network
    • Ryan Berube
    • Former Olympic Swimmer, Gold Medalist
    • Wealth Manager
    • UBS
    • Sibel Blau, MD
    • President/CEO
    • Quality Cancer Care Alliance Network
    • Medical Director, Oncology Division
    • Northwest Medical Specialties
    • Jeffrey Bockman, PhD
    • EVP, Oncology Practice Head
    • Defined Health, a Cello Health business
    • Alexis Bortniker, JD
    • Partner
    • Foley & Lardner LLP
    • Brian Bourbeau, MBA
    • Director, Business Metrics and Analysis, Clinical Affairs
    • American Society of Clinical Oncology
    • Lili Brillstein, MPH
    • CEO, Strategic Advisor, Value Based Healthcare, Episodes of Care & Bundled Payments
    • BCollaborative (Brillstein Collaborative Consulting)
    • Joshua Brody, MD
    • Director, Lymphoma Immunotherapy Program
    • Icahn School of Medicine at Mount Sinai
    • Barry Brooks, MD
    • Medical Director and Chairman
    • The US Oncology Network P&T Committee
    • McKesson Specialty Health
    • Rob Butcher
    • CEO/Founder
    • Swim Across America
    • Bob Charles, MBA
    • Founder/Principal
    • GeneriSys
    • Blair Childs
    • SVP, Public Affairs
    • Premier
    • Jim Clement
    • Partner/Co-Founder
    • Coeus Consulting Group, Coeus Healthcare
    • Charles Coltman
    • Founder/CEO
    • CancerLife
    • Monica Dean
    • Director, National Navigation Roundtable
    • American Cancer Society
    • Luis Diaz, MD
    • Head, Division of Solid Tumor Oncology
    • Memorial Sloan Kettering Cancer Center
    • Ron DiGiaimo, MBA
    • CEO/Chairman
    • Revenue Cycle, Inc.
    • Christian Downs, MHA, JD
    • Executive Director
    • Association of Community Cancer Centers
    • Eric Dozier
    • VP, Oncology North America
    • Lilly Oncology
    • Amy DuRoss
    • Co-Founder/CEO
    • Vineti
    • Andrea Dwyer
    • Co-Chair, National Navigation Roundtable
    • American Cancer Society
    • Amy Ellis
    • Director, Quality and Value-Based Care
    • Northwest Medical Specialties
    • Jonathon Fassberg
    • CEO
    • Solebury Trout
    • Torrie Fields, MPH
    • Senior Manager
    • Palliative Care Program Design & Implementation
    • Blue Shield of California
    • Benito Fernandez
    • VP, Trade Operations & Account Management
    • Onco360 Oncology Pharmacy
    • William Flood, MD
    • Chief Medical Officer, Eviti
    • NantHealth
    • Bo Gamble
    • Director, Strategic Practice Alliances
    • Community Oncology Alliance
    • Emily Gentry, RN, BSN, OCN
    • Oncology Navigation Consultant
    • Rose Gerber
    • Director, Patient Advocacy & Education
    • Community Oncology Alliance
    • Lisa Gill
    • Managing Director, Equity Research
    • JP Morgan
    • Gerry Gleeson, MBA
    • VP & US Head of Market Access
    • Sanofi
    • Rena Goins
    • Executive Director, Global Trade, GPO, & Distribution
    • Regeneron
    • Bob Gold
    • CEO and Chief Behavioral Technologist
    • GoMo Health
    • Russell Gollard, MD
    • Medical Director
    • OptumCare Cancer Care Optum
    • Judith Haber, PhD, APRN, BC, FAAN
    • Ursula Springer Leadership Professor in Nursing
    • NYU Rory Meyers College of Nursing
    • Author, Comprehensive Psychiatric Nursing
    • Mark Hagler
    • SVP/Head, Ophthalmics, Oncology & Long-Term Care
    • Sun Pharma
    • William Harwin, MD
    • Former CEO
    • Florida Cancer Specialists & Research Institute
    • Rob Butcher
    • CEO/Founder
    • Swim Across America
    • Mark Hiatt, MD
    • VP
    • Guardant Health
    • Mitch Higashi
    • Head, Health Economics and Outcomes Research
    • Bristol-Myers Squibb
    • Ross Hoffman, MD
    • Chief Medical Officer
    • Envolve Pharmacy Solutions
    • Anne Ireland, MSN, RN, AOCN
    • Executive Director, Community Practices & Outreach
    • Director at Large, Oncology Nursing Society Board
    • City of Hope
    • Scott Jauch
    • Sr. Director, Contact Strategy–Specialty
    • AstraZeneca
    • Ben Jones
    • VP
    • Government Relations & Public Policy
    • McKesson Specialty Health, The US Oncology Network
    • Kristi Jones
    • COO
    • NexImmune, Inc.
    • Robert Jones
    • Managing Director
    • Global Investment Research
    • Goldman Sachs
    • Mostafa Kamal
    • CEO
    • Magellan Rx Management
    • Ira Klein, MD, MBA, FACP
    • Senior Director
    • Healthcare Quality Strategy
    • Janssen Pharmaceuticals
    • Neal Lambert
    • Senior Director, Pricing Strategy Team Lead, US Biosimilars
    • Pfizer Oncology
    • Rick Lanman, MD
    • Chief Medical Officer
    • Guardant Health
    • Thomas LeBlanc, MD
    • Associate Professor of Medicine
    • Associate Professor in Population Health Sciences
    • Member of the Duke Cancer Institute
    • Duke University School of Medicine
    • Rick Lee, MBA, PhD
    • Executive Chairman
    • CancerLife
    • Roger Longman
    • Founder/Chairman
    • Real Endpoints
    • JoAnn Lovins, MS, RN
    • Service Line Director, Oncology
    • University of Colorado Health
    • Bryan Loy, MD, MBA
    • Physician Lead
    • Oncology, Laboratory, and Personalized Medicine
    • Health Care Services
    • Humana
    • Rusty Massey
    • VP
    • Strategic Accounts & Business Development
    • ION Solutions
    • Ali McBride, PharmD, MBA
    • Clinical Coordinator
    • University of Arizona Cancer Center
    • Mike McCarthy
    • Head, Access Marketing
    • Celgene
    • Bob McDonough, MD
    • Sr. Medical Director
    • Aetna
    • William McGivney, PhD
    • Managing Principal
    • McGivney Global Advisors
    • Annastasiah Mhaka, PhD
    • Senior Advisor
    • Adjuvant Partners
    • Co-Founder
    • Alliance for Artificial Intelligence in Healthcare
    • Brenda Nevidjon, MSN, RN, FAAN
    • CEO
    • Oncology Nursing Society
    • Lee Newcomer, MD
    • Former SVP, Oncology and Genetics
    • UnitedHealth Group
    • Kimberly Noonan
    • Founder and Chief Scientific Officer
    • WindMIL Therapeutics, Inc.
    • Jeffrey Patton, MD
    • CEO
    • Tennessee Oncology
    • Steve Peskin, MD
    • Executive Medical Director, Population Health
    • Horizon Blue Cross Blue Shield of New Jersey
    • Pete Perron
    • President, Provider Solutions
    • McKesson Specialty Health
    • Bruce Pyenson, FSA, MAAA
    • Principal and Consulting Actuary
    • Milliman, Inc.
    • Cynthia Radford
    • SVP
    • Innovatix & Essena
    • Dan Renick, RPh
    • President
    • Precision Value & Health
    • Christina Ritter, PhD
    • Director, Patient Care Models Group
    • Center for Medicare and Medicaid Innovation
    • Kent Rogers, MBA
    • SVP
    • Chief Formulary & Procurement Officer – Industry Relations
    • OptumRx
    • Darin Rubin
    • Partner and Managing Director
    • The Dedham Group
    • Morrie Ruffin
    • Managing Partner
    • Adjuvant Partners
    • Anil Rustgi, MD
    • Director
    • Herbert Irving Comprehensive Cancer Center
    • Columbia University
    • Alex Santini
    • EVP and Chief Commercial Officer
    • Lexicon
    • Don Sawyer
    • VP, US Market Access
    • Celgene
    • Mimi Schnier
    • Project Coordinator
    • Research Foundation, SUNY Old Westbury
    • Eric Schultz
    • Co-Founder
    • Ocean Genomics
    • Advisory Board
    • Center for Machine Learning and Health, Carnegie Mellon
    • John Simmons, PhD
    • Director, Translational Science and Diagnostics
    • PGDx
    • Jayson Slotnik, JD, MPH
    • Partner
    • Health Policy Strategies
    • Ted Snelgrove, MBA
    • Chief Business Officer
    • Lexent Bio
    • Charles Stevens, JD, MBA
    • VP
    • Access, Commercialisation, and Communications
    • ICON
    • Rob Stianchi
    • Director, US Oncology Marketing–Biosimilars
    • Merck
    • Brad Tallamy
    • Senior Director, Government Affairs
    • AmerisourceBergen
    • Michael Thompson
    • President/CEO
    • National Alliance of Healthcare Purchaser Coalitions
    • Barrett Thornhill, JD
    • Principal
    • The McManus Group
    • Deborah Toppmeyer, MD
    • Chief Medical Officer/Director
    • Stacy Goldstein Breast Cancer Center/Rutgers Cancer Institute of New Jersey
    • Michael Valenta
    • Executive Director
    • Oncology Organized Customer Marketing, Access and Reimbursement
    • Merck & Co.
    • Amy Valley, PharmD, BCOP
    • VP
    • Clinical Strategy & Technology Solutions
    • Cardinal Health
    • Joe Vandigo, MBA, PhD
    • Director, Policy & Research
    • Pharmaceutical Research and Manufacturers of America
    • Adria Warren, JD
    • Partner
    • Specialist, Healthcare Transactions
    • Foley & Lardner LLP
    • David Wierz
    • Senior Principal
    • The OCI Group, LLC
    • William Yoon, PharmD, MBA
    • Head, US External Engagement and Medical Advocacy
    • Sandoz Inc.

Edward Abrahams, PhD

President, Personalized Medicine Coalition

Edward Abrahams is President, Personalized Medicine Coalition, Washington, DC, where he manages the understanding and adoption of personalized medicine concepts, services, and products for the benefit of patients and the health system. Previously, Dr Abrahams was Executive Director, Pennsylvania Biotechnology Association, Malvern, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state.

For 7 years, Dr Abrahams worked for the US Congress, including as a Legislative Assistant to Senator Lloyd Bentsen, as an Economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as an American Association for the Advancement of Science Congressional Fellow for Representative Edward J. Markey.

Brian Agnew

Senior Director, US Policy, Pfizer

In his 17 years at Pfizer, Brian Agnew has had responsibility for policy analytic projects of increasing scope. Currently, he leads the US state and federal policy teams, which are responsible for assessing developments, including state pricing initiatives, changes to the Affordable Care Act, and new Medicare Part B and Part D payment models. He also leads the Canada policy team. He and his teams partner with health economists to explore issues of benefit design and healthcare system efficiency to inform payer and policymaker decision- making. Prior to joining Pfizer, he spent 8 years at the Health Care Financing Administration (now the Centers for Medicare & Medicaid Services) writing quality improvement regulations. He holds an MBA from the Yale School of Management and a bachelor’s degree in economics from Dartmouth College.

Gail Airasian, MBA

Vice President, Sales and Services, Flatiron Health

Gail Airasian is Vice President, Sales and Services, Flatiron Health, New York City, where she is responsible for overseeing the revenue cycle management software and services and sales of Flatiron’s OncoCloud, a cloud suite to meet the technology needs of the community practice of the future. Prior to her current role, she was Executive Director, Client Solutions, athenahealth, Watertown, MA, where she oversaw sales engineering, product demonstration, training, and client advocacy programs. She was also Director of Operations for Brigham and Women’s Hospital, Boston, MA.

Ms Airasian received her bachelor’s degree in Middle East studies from Wellesley College, and her master’s in business administration with a focus in finance from Boston College, MA.

Cheryl Allen, PharmD, MBA

Principal Consultant, Blue Fin Group

Cheryl Allen is Principal Consultant, Blue Fin Group, Philadelphia, PA, where she utilizes more than 2 decades of industry experience as a passionate supporter of the development of specialty pharmaceuticals to create patient-centric solutions on behalf of pharmaceutical industry stakeholders. Prior to her current role, Ms Allen was Vice President, Business Development and Industry Relations, Diplomat Specialty Pharmacy, Flint, MI, and Senior Director, Clinical Services, Sanovia Corporation, Philadelphia, PA, where she managed new product development and sales support.

Ms Allen received her bachelor’s degree in pharmacy from Samford University, McWhorter School of Pharmacy, Homewood, AL, and her master’s degree in business administration from Saint Joseph’s University, Erivan K. Haub School of Business, Philadelphia, with a focus on pharmaceutical and healthcare marketing.

James Almas, MD

Vice President and National Medical Director, Clinical Effectiveness, LabCorp

James Almas is Vice President and National Medical Director for Clinical Effectiveness at LabCorp.

He is a board-certified pathologist with years of experience in hospitals, independent laboratories, and with service to Medicare.

Dr Almas recently served as contract medical director as Medical Director of the MolDX Program at Palmetto GBA. There he oversaw coverage and reimbursement (through the MolDX Program) for 28 states for Medicare. Prior to that service, Dr Almas was a medical officer in the Coverage and Analysis Group at the Centers for Medicare & Medicaid Services. At Medicare, he was responsible for the National Coverage Determinations in the area of laboratories and was involved with the parallel review process (with the US Food and Drug Administration) for the Foundation Medicine application.

He is past Chief of Staff at St. Dominic-Jackson Memorial Hospital and past Medical Director of Pathology at St. Dominic, a 500-bed acute care general hospital.

From 2006 to 2010, Dr Almas was the College of American Pathologists AMA/CAP CPT-Advisor to the CPT Editorial Panel.

Prior to 1994, he practiced in Los Angeles County, CA, and he was the elected and served as President of the Medical Staff at Pomona Valley Hospital Medical Center. He also served as Physician-in-Chief for Valley Independent Physicians, an independent physician association associated with a regional health plan (Inter Valley Health Plan, a federally qualified health maintenance organization).

Rachel Anhorn, PharmD

Director, Payer Policy and Health Outcomes, Foundation Medicine

Rachel Anhorn is Director, Payer Policy and Health Outcomes, Payer Relations and Reimbursement Team, Foundation Medicine, Cambridge, MA, where she leads the development of US Health Economics & Outcomes Research and Real-World Evidence initiatives at Foundation Medicine. Prior to this role, Dr Anhorn was Regional Scientific Manager, Health Outcomes and Pharmacoeconomics, Hospira, Boston, MA; Field Medical Director, Biosimilars, Pfizer, Boston; and Associate Director, Health Economics & Outcomes Research, Boehringer Ingelheim, Minneapolis-St. Paul, MN.

Dr Anhorn received her bachelor’s degree in biochemistry from the University of Wisconsin-River Falls, and her doctorate in pharmacy from the University of Minnesota College of Pharmacy, Minneapolis.

Peter Bach, MD



Joe Baffone

Co-Founder/CEO, Annexus Health

Joe Baffone leads the overall business development, strategy, and culture of Annexus Health. He ensures the delivery of an enterprise platform that manages logistics throughout the patient journey.

Prior to co-founding Annexus Health, he spent 7 years as a principal at onPoint Oncology, where he concepted, built, implemented, and monetized cancer access solutions. His key areas of focus were data analytics, application of intelligence to the analytics, and point-of-care solutions embedded in electronic medical/health records.

Earlier, he spent more than 20 years working in life sciences. Most of his time was dedicated to the business of oncology, where he established strategies and led teams dedicated to contracting, pricing, reimbursement, payer, and access functions, as well as establishing and maintaining strategic relationships with key oncology organizations.

Ray Bailey, BPharm, RPh

Pharmacy Director, Rx to Go, Florida Cancer Specialists’ Oral Oncology Specialty Pharmacy

Ray Bailey is Pharmacy Director, Rx to Go, Florida Cancer Specialists’ Oral Oncology Specialty Pharmacy, Ft. Myers, FL, where he oversees the operations, including financial management, business development, new drug access, purchasing contracts, and overall formulary management.

Prior to his current position, Mr Bailey was General Manager, Walgreens/OptionCare of SW Florida, Ft. Myers, after the sale of his franchise of OptionCare, where he was responsible for home medical services, including home infusion and nursing and the clinical respiratory and specialty pharmacy. He is currently involved in professional societies, such as the Community Oncology Alliance, the Florida Pharmacy Association, the Florida Society of Health-System Pharmacists, and the Hematology Oncology Pharmacist Association. He currently is an Advisory Board Member for the Community Oncology Pharmacy Alliance and the National Community Oncology Dispensing Association.

Mr Bailey attended the pre-pharmacy curriculum at Mercer University, Macon, GA, and obtained his bachelor’s degree in pharmacy from the University of Georgia School of Pharmacy, Athens.

Kendra Barber, MHA, RN, OCN



Pat Basu, MD, MBA

President and Chief Executive Officer, Cancer Treatment Centers of America Global

Pat Basu is President and Chief Executive Officer, Cancer Treatment Centers of America Global, Chicago, IL, which includes the Cancer Treatment Centers of America (CTCA) Comprehensive Cancer Care Network of hospitals and outpatient care centers and new business ventures. Previously, he served as a White House Fellow and Senior Advisor for President Obama’s economic and health agenda.

Dr Basu helped start Doctor On Demand, the nation’s largest provider of telehealth video visits, which partners with insurers and employers to provide access to more than 30 million Americans. Prior to this, he co-founded Extend MD, a web portal designed to enhance outpatient care and STARS Luncheon, a nonprofit that supports the career success of disadvantaged children. He currently provides care to veterans at the Veterans Administration Hospital System.

He received his bachelor’s degree in mechanical engineering from the University of Illinois at Urbana-Champaign; his master’s degree in business administration and management at the University of Chicago Booth School of Business, IL; and his medical degree from the University of Chicago, IL.

Sarah Beadling




Professor of Medicine, Robert H. Lurie Cancer Center, Northwestern University

Past Chair, National Comprehensive Cancer Network

Dr Benson is Professor of Medicine in the Division of Hematology/Oncology at Northwestern University’s Feinberg School of Medicine in Chicago, IL. He is also Associate Director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award (Fellow of ASCO). Dr Benson has been a member of and chaired a number of committees. He is the immediate past chair of the ECOG-ACRIN Gastrointestinal Committee and the current chair of the Data Monitoring Committee, co-chair of the CCDR Committee and a member of the National Cancer Institute Rectal/Anal Task Force. He is chair of the International Rare Cancers Initiative, Anal Cancers Committee, and member of the Small Intestinal Cancer Committee. In addition, he is Past President of the Illinois Medical Oncology Society, Past President of the Association of Community Cancer Centers, a board member and past chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN), and a member of the Board of Directors of the NCCN Foundation. He is the chair of both the NCCN Hepatobiliary Guidelines Panel and of the Colon, Rectal and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine Panels. He is a past president of the International Society of GI Oncology. Dr Benson is a member of the Executive Committee of the Patient Advocate Foundation and the National Patient Advocate Foundation (president); additionally, he is a medical advisory board member for both Debbie’s Dream Foundation: Curing Stomach Cancer and Fight Colorectal Cancer.

Jeff Berkowitz, JD

Chief Executive Officer, Real Endpoints

Jeff Berkowitz is Chief Executive Officer, Real Endpoints, Madison, NJ. Prior to this position, he was Executive Vice President, UnitedHealth Group, Cambridge, MA; President, Global Pharma and Market Access, Walgreens Boots Alliance; and Senior Vice President, Global Market Access, Merck. Mr Berkowitz has more than 20 years of experience in most key verticals in global healthcare with executive committee and other senior roles.

Mr Berkowitz received his bachelor’s degree in political science from Union College, Schenectady, NY, and his law degree from Brooklyn Law School, NY. He currently serves on the Board of Directors for Zealand Pharma, Esperion Therapeutics, and Infinity Pharmaceuticals.

Larry Blandford, PharmD

Executive Vice President, Customer Solutions, Precision for Value

Larry Blandford is Executive Vice President, Customer Solutions, Precision for Value, New York, NY, where he oversees the global market access services in health economics, pricing, and access strategy. Prior to his current position, Dr Blandford was Executive Vice President, Managing Director, Hobart Group Holdings, Gladstone, NJ, and Area Vice President, Physician Connectivity, CVS Caremark, where he led initiatives in physician connectivity and electronic prescribing programs, and developed strategic relationships with key payer clients.

Dr Blandford has authored and co-authored publications in journals such as the Journal of Managed Care Pharmacy related to medication utilization and value. He is also an active member of professional organizations such as the Academy of Managed Care Pharmacy and the International Society for Pharmacoeconomics and Outcomes Research.

Dr Blandford received his Doctor of Pharmacy degree from the University of Kentucky College of Pharmacy, Lexington, and completed his managed care pharmacy residency training at Advance Paradigm and the University of Maryland School of Pharmacy.

Sibel Blau, MD

President/CEO, Quality Cancer Care Alliance Network; Medical Director, Oncology Division, Northwest Medical Specialties

Sibel Blau is a medical oncologist who has been in clinical practice since 2001 after completion of her Stem Cell Fellowship at Fred Hutchinson Cancer Research Center. In addition to her work as a breast oncologist, Dr Blau has taken leadership roles in developing breast cancer programs of excellence in her region. She is also very involved with clinical research programs at Northwest Medical Specialties, where she is Medical Director for the Hematology-Oncology Division and heads the Precision Medicine Program.

She is one of the founding members and President/Chief Executive Officer of the Quality Cancer Care Alliance Network, a national organization to form a value-based care organization that improves the cost and quality of cancer patients treated in independent practices throughout the nation. Dr Blau is also the immediate past president of Washington State Medical Oncology Society and a member of All4Cure as a clinical oncologist.

Jeffrey Bockman, PhD



Alexis Bortniker, JD



Brian Bourbeau, MBA

Director, Business Metrics and Analysis, Clinical Affairs, American Society of Clinical Oncology

Brian Bourbeau is Director, Business Metrics and Analysis, Clinical Affairs, American Society of Clinical Oncology (ASCO), Washington, DC. In this role, he oversees various practice health initiatives and payment reform efforts within ASCO.

Prior to ASCO, Mr Bourbeau was Director, Practice Operations, Oncology Hematology Care, Cincinnati, OH, where he oversaw quality programs, managed care, and revenue cycle operations. His experience with alternative payment models includes multiple Medicare, Medicaid, and commercial programs, in addition to Manager, Financial Systems, Lee Memorial Health Systems, Fort Myers, FL; Consultant, Revenue Cycle Support, University of Cincinnati Medical Center, OH; and Quality and Operations Improvement, The Ohio State University Medical Center, Columbus.

Mr Bourbeau received his master’s degree in business administration from Franklin University, Columbus, OH, and holds certifications in Lean, Six Sigma, and Business Intelligence.

Scott Breidbart, MD, MBA

Chief Medical Officer, Affinity Health Plan

Scott Breidbart is Chief Medical Officer, Affinity Health Plan, New York, NY, where he oversees the Medical Management, Pharmacy Management, Quality Management, and Risk Management departments. He currently is the face of Affinity Health Plan to many medical groups, hospitals, and regulators, and is credited with reformulating the company’s utilization management structure to include monitoring and accountability.

Dr Breidbart’s experience in managed care spans more than 2 decades and includes executive positions as Chief Medical Officer, Solera Health, Phoenix, AZ; Chief Clinical Officer, EmblemHealth, New York, NY; Chief Medical Officer, Empire Blue Cross Blue Shield, New York, NY; and National Vice President of Medical Policy and Quality Improvement, Health Net, Shelton, CT. Prior to his managed care career, Dr Breidbart practiced pediatric endocrinology for 10 years at New York Medical College, Valhalla, NY.

Dr Breidbart obtained his bachelor’s degree in mathematics from Yale University, New Haven, CT; his medical degree from Columbia University Vagelos College of Physicians and Surgeons, New York, NY; and his master’s degree in strategic management from Pace University Lubin School of Business, White Plains, NY.


Chief Medical Officer, Predictive Health

Joel Brill is Chief Medical Officer, Predictive Health, Phoenix, AZ, and Assistant Clinical Professor, Medicine, University of Arizona College of Medicine, Tucson. Prior to his current positions, Dr Brill was Chief Medical Officer, Early Bird Alert, San Francisco, CA; Chief Medical Officer, Gila River Health Care, Phoenix, AZ; and Medical Director, Blue Shield of California, Sacramento.

Dr Brill currently participates on scientific advisory boards and committees for several managed care companies and works extensively with the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association on coding, coverage, and reimbursement issues. He co-chaired the Part D medication measures on the Technical Expert Panel for CMS.

Dr Brill received his associate’s degree in biology from the University of California Los Angeles, and his medical degree from Chicago Medical School at Rosalind Franklin University of Medicine and Science, OH.

Lili Brillstein, MPH



Joshua Brody, MD



Barry Brooks, MD

Chairman, Pharmacy and Therapeutics, Texas Oncology/US Oncology Network

Barry Brooks is Chairman, Pharmacy and Therapeutics, Texas Oncology/US Oncology Network, Woodlands, TX, where he has served as its physician lead on the US Oncology drug contracting committee since 2005, and founded the US Oncology’s Pathways Task Force, which puts clinical pathways into everyday use in oncology practice. In addition, Dr Brooks also serves as Medical Director, Oral Oncolytics, for McKesson Specialty Health and the US Oncology Network, and still sees patients when he is not speaking with drug manufacturers, providers, and pharmacists about all aspects of oncology medication.

Dr Brooks is a member of the National Community Oncology Dispensing Association executive committee and is an active member of the US Oncology and Texas Oncology legislative political action committees, where he advocates for the interests of community oncology.

He received his medical degree from The University of Texas Southwestern Medical Center at Dallas. He completed his residency in internal medicine and his hematology/oncology fellowship at Parkland Memorial Hospital, Dallas, TX, and Dallas VA Medical Center.

Eslyn Byarm, RN, BSN, CCM, AATMC

Health Risk Strategist, Clinical Risk Management Services, Berkley Accident and Health

Eslyn Byarm is Health Risk Strategist specializing in Berkley’s captive insurance segment and is part of Berkley Accident and Health’s Berkley Edge program. She works with self-insured employer groups and their consultants in relation to clinical education and mitigating risk on a variety of current and emerging health risk management topics. The scope of these discussions includes the full continuum of health risk strategies, including both employer-level first dollar to stop-loss–level catastrophic exposures focusing on both improved fiscal and health outcomes. For the past 4 years, she has been an active moderator and speaker at Berkley’s annual captive symposium as well as other Berkley captives’ risk management workshops.

She earned her bachelor’s degree in nursing from Columbia Union College (now known as Washington Adventist University) and has more than 30 years of experience as a registered nurse, including working in the emergency room of an inner-city trauma center, as well as several positions at various insurers. She has been a Certified Case Manager (CCM) for more than 10 years. She resides in New Jersey, working in Berkley’s Hamilton office.

Chris Byrne

Vice President, Strategic Accounts, Oncology Supply, AmerisourceBergen

Christopher Byrne is Vice President, Strategic Accounts, Oncology Supply, an AmerisourceBergen company, Northport, NY, where he is responsible for the management, retention, and growth of Oncology Supply Distribution sales to large, national, and regional community oncology accounts and health system clinics. Prior to his current role, Mr Byrne was the Northeast Account Manager/East Region Sales Director for the company.

Mr Byrne has more than 20 years of experience in the pharmaceutical sales landscape, including National Accounts Manager, Oncology, Aventis Pharmaceutical, where he was responsible for the promotion, sales, and marketing of Aventis Oncology Therapeutics’ portfolio.

Mr Byrne obtained his bachelor’s degree in architectural engineering/construction management and business administration from the New York Institute of Technology, Old Westbury.

Neil Canavan

Scientific Advisor, Solebury Trout

Neil Canavan is a veteran science journalist with more than 20 years of experience reporting on the technologies of drug development, focusing, of late, on the unprecedented advances in the field of immuno-oncology. Leveraging his extensive relationships with life science investigators, he authored A Cure Within: Scientists Unleashing the Immune System to Kill Cancer, published in 2017 by Cold Spring Harbor Laboratory Press.

Bob Charles, MBA



Blair Childs



Jim Clement



Charles Coltman



Gena Cook

Founder & President, Navigating Cancer

Gena Cook is Founder and President, Navigating Cancer, Seattle, WA, where she leads the innovation and corporate strategy and development. Her vision of leveraging technology to improve patient care in the era of precision medicine and value-based care led her to founding Navigating Cancer, where she was Chief Executive Officer for its first 10 years. Prior to her current role, Ms Cook was Vice President, Sales and Marketing, McKesson Specialty Care Solutions, and Vice President, Oncology Therapeutics Network.

Ms Cook has spent her career in oncology—launching and growing technology, distribution, healthcare services, data, and pharmaceutical products. She currently serves as Chair of the National Comprehensive Cancer Network Foundation Board and is Director of the Washington Technology Industry Association Benefit Trust.

Ms Cook received her bachelor’s degree in business administration from the University of Washington, Seattle.

Steven D’Amato, RPh, BSPharm, BCOP

Executive Director and Clinical Pharmacy Specialist, New England Cancer Specialists

Steven D’Amato is Executive Director and Clinical Pharmacy Specialist, New England Cancer Specialists, Scarborough, ME, and Clinical Associate Professor, University of Tufts College of Medicine, Boston, MA. He has more than 30 years of experience in clinical oncology in hospital and private practice settings with an extensive knowledge of electronic medical record implementation, utilization, and practice management.

Mr D’Amato has lectured extensively on pain management, end-of-life care, and oncology practice. He is a member of the American Society of Clinical Oncology, the American College of Clinical Pharmacy, the Association of Community Cancer Centers, and the Hematology/Oncology Pharmacy Association. He is a board member of the Community Cancer Center, South Portland, ME, a nonprofit organization providing education and support to cancer patients. He is Past President of the Association of Community Cancer Centers and is the Delegate Representative for New England Cancer Specialists.

He received his bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy, Boston.

Monica Dean

Director, Patient Navigation, American Cancer Society

Monica Dean is Director, Patient Navigation, and the National Navigation Roundtable (NNRT), American Cancer Society, Atlanta, GA. She is responsible for directing long-term activities, developing strategic concepts, and overseeing the implementation of the NNRT activities and initiatives, while maintaining high-level collaborative partnerships with external partners and NNRT member organizations. In her role, she also provides leadership and implementation support to the American Cancer Society patient navigator program, which consists of 60 nonclinical patient navigators in healthcare systems across the country.

Ms Dean began her career with the society in 2001 with the South Atlantic Division, serving in mission delivery and cancer control positions, before moving into a national patient navigation position at the society’s global headquarters in 2012. During her 18-year career with the American Cancer Society, she has contributed to a variety of initiatives at the state, regional, and national levels. She is also an active member of the Academy of Oncology Nurse & Patient Navigators.

She received her bachelor’s degree in health science with a minor in nutrition from Georgia Southern University.

Brian DeBusk, PhD, MBA

President and Chief Executive Officer, DeRoyal Industries

Brian DeBusk is President and Chief Executive Officer, DeRoyal Industries, Knoxville, TN. DeRoyal is one of the nation’s largest privately held medical equipment and device companies, specializing in the design, manufacture, and marketing of surgical supplies, orthopedic goods, patient protection items, and wound care products. Dr DeBusk also currently serves as Vice Chairman, Lincoln Memorial University, Harrogate, TN, which houses the largest medical program in the state of Tennessee at the DeBusk College of Osteopathic Medicine.

In 2016, Dr DeBusk was appointed to the Medicare Payment Advisory Commission, where he engaged in payment appropriateness and adequacy to delivery reform for Part A and Part D drug policies. Prior to this, he was Founder of iPath, which pioneered the development of many features found in modern-day Operating Room Information Systems, including block scheduling, charge by exception, in-room clinical documentation, rules-based charging, tiered preference cards, and structured bills of material.

Dr DeBusk obtained his bachelor’s degree in engineering and his doctorate in engineering from Vanderbilt University, Nashville, TN. He obtained his master’s degree in business administration and management from Emory University, Atlanta, GA.

Luis Diaz, MD



Gabriela Dieguez, FSA, MAAA

Principal and Consulting Actuary, Milliman, Inc.

Gabriela Dieguez is Principal and Consulting Actuary, Milliman, Inc., New York, NY, where she provides actuarial and consulting services to a wide range of clients, including life science companies, commercial insurers, Medicare Advantage organizations, healthcare insurance companies, and healthcare providers. She has extensive experience in pricing health plans, analyzing benefit utilization, forecasting medical trends, performing financial projections, and claim reserve analysis.

She has certified Medicare Advantage and Part D bids for several Medicare Advantage organizations over the past decade and is an expert in Part D and pharmacy benefit issues. Her consulting with life science companies focuses on real-world analytics, patient affordability issues, value-based contracts, and formulary analysis. She has extensive knowledge of the Medicare Advantage and Part D risk score methodology, market landscape, and regulatory and proposed reform environment.

Ms Dieguez obtained her bachelor’s degree in actuarial science from the University of Buenos Aires, Argentina.

Ron DiGiaimo, MBA



Christian Downs, MHA, JD



John Doyle, PhD

VP, Global Healthcare Innovation Lead, Pfizer

John Doyle leads the Patient Health & Impact Global Healthcare Innovation Center at Pfizer. His team designs new models of access, value-based contracting, innovative financing, and forges new partnerships across the healthcare sector to facilitate the move to value-based healthcare.

Prior to joining Pfizer, Dr Doyle led the Global Enterprise Solutions team at IQVIA, providing technology-enabled real-world evidence platforms and research networks to help transform biopharmaceutical industry engagement with healthcare systems worldwide. Before that, he led the Global Value & Outcomes Center of Excellence at Quintiles, overseeing innovative pricing and market access, policy analysis, and health economics and outcomes research. Prior to joining Quintiles, he served as President of Analytica International, providing health economics, outcomes research, and real-world evidence services to the global biopharmaceutical industry. Before co-founding Analytica, he led the Health Economics Research team for the Center for Health Outcomes and Economics at Bristol-Myers Squibb Company.

Dr Doyle has more than 25 years of experience working in the industry and is very active in thought leadership, including representing the contract research organization industry in the National Academies of Sciences, Engineering, and Medicine’s Real-World Evidence Workshop and co-chairing the Alliance for Regenerative Medicine Foundation’s Economic Impact Steering Committee. He has published more than 50 peer-reviewed articles and serves as Adjunct Assistant Professor of Epidemiology at Columbia University.

He earned a doctorate and master’s of public health degree in epidemiology from the Mailman School of Public Health at Columbia University and a bachelor’s degree in business management and applied economics with a concentration in the life sciences at Cornell University.

Eric Dozier



Jesse Dresser, JD

Partner, Frier Levitt, LLC

Jesse Dresser is Partner at Frier Levitt, LLC, Life Sciences Department and heads the firm’s Pharmacy Practice Group. His practice is dedicated to representing a broad cross-section of pharmacies and pharmacy providers, including community retail pharmacies, chain pharmacies, compounding pharmacies, specialty pharmacies, mail-order pharmacies, home infusion providers, and dispensing physician practices. He represents pharmacy providers nationally regarding issues with payers and pharmacy benefit managers (PBMs), including PBM audit appeals, network terminations, network access and credentialing applications, and reimbursement issues.

In addition to his work with pharmacy clients, he also represents a variety of other entities across the healthcare and life sciences spectrum, including other healthcare providers, pharmaceutical and biotech manufacturers, pharmaceutical wholesalers and distributors, and healthcare technology companies. Through this work, he has focused on the intersection between the law and economic considerations, including drug pricing, marketing techniques, and benefits management.

Mr Dresser frequently lectures across the country at national and regional pharmacy and healthcare conferences and organizations, including the International Academy of Compounding Pharmacists, the American College of Apothecaries, the American College of Veterinary Pharmacists, the National Association of Specialty Pharmacy, the Community Oncology Alliance, and the Community Oncology Pharmacy Association. He also regularly hosts pharmacy industry webinars for a variety of industry organizations and affiliated companies. In addition to lecturing, he has been published or quoted in a variety of internationally circulated publications and media.

He joined Frier Levitt in 2010 after graduating magna cum laude from Seton Hall University School of Law. Previously he served as a judicial intern to the Honorable Dickinson R. Debevoise, former Senior District Judge of the US District Court for the District of New Jersey.

Amy DuRoss



Andrea Dwyer



Marc Earl, PharmD, BCOP

Assistant Director, Pharmacy, Cleveland Clinic

Marc Earl is Assistant Director of Pharmacy at the Cleveland Clinic. He oversees inpatient and outpatient oncology pharmacy services at the Taussig Cancer Center and 12 regional oncology infusion sites. The pharmacy department, in conjunction with the Taussig Cancer Center, provides pharmacy services for more than 14,000 patients per year. He has worked with the Taussig Cancer Center for 15 years in a variety of pharmacy roles. He has been involved in the expansion of oncology pharmacy services, implementation of chemotherapy computerized physician order entry modules in adult and pediatric oncology, and design of USP 797- and 800-compliant oncology sterile product areas.

Mike Einodshofer, RPh, MBA

Chief Pharmacy Officer, Maxor National Pharmacy Services

Michael Einodshofer joined Maxor National Pharmacy Services in August 2016 as Chief Innovation Officer. At Maxor, he has responsibilities for corporate strategy, product development, analytics, reporting, and technology solutions that span across Maxor’s pharmacy benefit manager, specialty pharmacy, and pharmacy operations assets. He has been involved in the pharmacy industry for more than 20 years, having previously held leadership positions within a specialty pharmacy, a health plan, and a hospital system.

Immediately prior to joining Maxor, he was Senior Director of Specialty Strategy and Innovation at Walgreens, where he helped lead the organization to become the third largest specialty pharmacy in the United States. While there, he led the development of specialty clinical and cost-containment strategies, reporting and analytics, and sales and marketing efforts.

Mr Einodshofer also brings with him 6 years of leadership from within UPMC Health Plan, a major regional health plan in Pennsylvania now serving more than 1 million members. While there, he led the administration of pharmacy services to all health plan beneficiaries, oversaw pharmacy benefit manager contracting and management, led medical and pharmacy analytics, Medicare Part D functions, and call center operations.

He has researched and published many articles on cost-effectiveness of specialty therapies and the importance of cost-containment programs, built several pharmacy software platforms, and is a frequent public speaker on specialty pharmacy topics throughout the country. He holds a bachelor’s degree in pharmacy and a master’s degree of business administration from the University of Pittsburgh.

Amy Ellis

Director, Quality and Value-Based Care, Northwest Medical Specialties

Amy Ellis is Director of Quality and Value-Based Care at Northwest Medical Specialties, and oversees their value-based care initiatives and works to continually transform the way care is provided to patients by utilizing innovative tools such as artificial intelligence, continual process improvement, and data analysis. She brings 14 years of healthcare experience to the Northwest Medical Specialties team, including outpatient radiology and clinical oncology research. Her primary focus is to support practice transformation by meeting the quality and cost metrics put into place by the various value-based care programs at the practice.

Jonathon Fassberg



Torrie Fields, MPH



Benito Fernandez

Vice President, Trade Operations & Account Management, Onco360 Oncology Pharmacy

Benito Fernandez joined Onco360 in 2012 and is responsible for the development, execution, and maintenance of Onco360’s limited distribution and trade operations, which encompass contracting, program implementation, reporting, and account management. Under his leadership, Onco360 has experienced exponential growth in limited distribution products and patient support program offerings to patients and physicians.

Over the past 2 years, Onco360 has added more than 20 new specialty drugs to the portfolio, establishing new partnerships with both big and small pharma/biotech manufacturers. Onco360’s current pipeline is also more robust than it has been in the history of the company. In addition to increasing Onco360’s product access, he has driven revenue growth through their exceptional fee-for-service programs, cutting-edge clinical programs, and industry leading data and technology services.

Prior to joining Onco360, he served in a variety of progressively senior roles with Medco Health Solutions and Horizon Blue Cross Blue Shield of New Jersey, supporting finance, data reporting, and analytics services. He brings more than 12 years of health plan and pharmacy benefit management experience with a track record of driving operational excellence by optimizing business processes, adapting to change, and challenging existing practices.

Nicolas Ferreyros

Director, Communications, Community Oncology Alliance

Nicolas Ferreyros is Director, Communications, Community Oncology Alliance, New York, NY, the only national organization dedicated solely to preserving and protecting local, affordable, and accessible cancer care. Prior to his current position, Mr Ferreyros was Managing Supervisor, GYMR Public Relations, Washington, DC, where he oversaw campaigns for the Robert Wood Johnson Foundation, American Board of Internal Medicine, Consumer Reports, and numerous federal agencies.

Mr Ferreyros has engaged in recent health policy issues before Congress and regulatory agencies, including the Affordable Care Act, the 340B Drug Discount Program, Medicare reimbursement policy, and more. He has also worked closely with policymakers on Capitol Hill, the White House, the Department of Health & Human Services, the US Food and Drug Administration, and the National Institutes of Health.

Mr Ferreyros received his bachelor’s degree in political science from McGill University, Montreal, Canada.

William Flood, MD



Kelly Franchetti, RN, CCRN, CEN

Vice President, Global Patient Insights and Engagement, ICON

Kelly Franchetti is Vice President, Global Patient Insights and Engagement, ICON, Philadelphia, PA, where she maintains and continually improves services, tools, and methods of patient-centered solutions on a global scale by recruiting and retaining patients for late-phase projects. Ms Franchetti has been a critical care nurse for more than 20 years and still maintains her nursing practice at Temple University Hospital, Philadelphia. Throughout her clinical research experience, she has exceptional insights in the solid understanding of the process and components in the drug development process combined with patient and clinical knowledge.

Prior to her current position at ICON, she was Vice President, Clinical Insights & Strategy, inVentiv Health, Newton, PA, and Associate Director, Business Development, ePharmaSolutions, Plymouth Meeting, PA. She founded the New Jersey chapter of the Safe Kids Coalition, where she worked directly with legislators to change state laws to enhance safety for children.

Ms Franchetti received her registered nursing license from Drexel University College of Nursing and Health Professions, Philadelphia, PA.

Daniel Frier, JD

Co-Founding Partner, Frier Levitt, LLC

Daniel Frier co-founded the healthcare law firm of Frier Levitt, LLC in 2000, and is chairman of the firm's healthcare department after many years of dedicating his practice to representing all manner of healthcare providers across the full gamut of healthcare-related legal matters. He graduated from Franklin & Marshall College in 1990 before he went on to pursue a Juris Doctor degree from Temple University School of Law, where he graduated cum laude in 1994, and was editor of the Temple Law Review.

His more than 20 years of experience in healthcare law includes the representation of a diverse group of healthcare clients, including physicians, physician practices, pharmacies, ambulatory surgical centers and imaging centers, sleep centers, laboratories, and private equity groups, concerning a wide range of corporate, transactional, and regulatory issues. He also provides clients with strategic advice on how to adjust their operations to keep pace with the quickly changing healthcare marketplace. He works with clients on practice formations and sales, fraud and abuse and Stark counseling, buy-sell agreements, employment issues, large group practice consolidations, HIPAA compliance, and governmental, professional board, and medical staff investigations. Because so much of healthcare law is federal in nature, he has clients across the country, and has a national presence in the formation of large group medical practices.

He is a frequent lecturer across the country on issues such as group practice formation, clinically integrated networks, value-based contracting models, fraud and abuse compliance, and other health law–related topics.

John Frownfelter, MD, FACP

Chief Medical Information Officer, Jvion

John Frownfelter is an internist and physician executive in health information technology and is currently leading Jvion’s clinical strategy as their Chief Medical Information Officer. With 20 years’ leadership experience he has a broad range of expertise in systems management, care transformation, and health information systems. Dr Frownfelter has held a number of medical and medical informatics leadership positions over nearly 2 decades, highlighted by his role as Chief Medical Information Officer for Inpatient Services at Henry Ford Health System and Chief Medical Information Officer for UnityPoint Health, where he led clinical IT strategy and launched the analytics programs. Since 2015, Dr Frownfelter has been bringing his expertise to healthcare through health IT advising to both industry and health systems. His work with Jvion has enhanced their clinical offering and their implementation effectiveness. He has also held professorships at St. George’s University and Wayne State schools of medicine, and the University of Detroit Mercy Physician Assistant School. Dr Frownfelter received his medical degree from Wayne State University School of Medicine.

Judith Gallagher, MBA, PA-C

Senior Director, Clinical Product Development, Envolve Pharmacy Solutions

Judith Gallagher is Senior Director, Clinical Product Development, Envolve Pharmacy Solutions, Orlando, FL, and is Founder and Managing Partner, Channel Health Advisors, Louisville, KY. She has more than 30 years of healthcare experience across a spectrum of provider and payer systems. Her expertise and leadership include clinical strategy development and program design, quality improvement, and operational oversight resulting in moving complex problems to operational success.

Prior to her current position, she was Director, Complex Care Clinical Strategy, Humana, Louisville, where she designed and implemented a broad range of programming, including direct-to-consumer self-management programs and provider-facing quality and value-based designs. As a physician assistant, her early career roles included research, clinical, and administrative leadership positions within nephrology and oncology university-based programs and within managed care organizations to provide strategic and operational oversight of utilization management, care management, and quality programs.

Ms Gallagher received her bachelor’s degree and physician assistant certification from Saint Francis University, Loretto, PA, and her master’s degree from Michigan State University Eli Broad College of Business, East Lansing.

Bo Gamble



Stuart Genschaw

Chief Executive Officer, Cancer & Hematology Centers of Western Michigan

Stuart Genschaw is Chief Executive Officer for Cancer & Hematology Centers of Western Michigan. The practice has numerous locations throughout West Michigan. He serves on many local, state, and national boards, such as the Community Oncology Alliance. He is an active consultant and advisor to physician practices and pharmaceutical companies. He received his MHA degree from Western Michigan University and his MBA degree from the University of Colorado.

Emily Gentry, RN, BSN, OCN



Sharon Gentry, MSN, RN, AOCN, CBCN, HON-ONN-CG

Breast Nurse Navigator, Novant Health

Sharon Gentry is part of an ongoing successful breast nurse navigator program at the Novant Health Derrick L. Davis Cancer Center. She is an interdisciplinary team member connecting 2 hospitals, a breast mammography clinic, a regional cancer center, a surgical office, and a variety of community resources in Winston-Salem, NC. She received her bachelor’s degree in nursing at the University of North Carolina at Chapel Hill and her master’s degree in nursing education at the University of North Carolina at Greensboro.

She has been a member of the Academy of Oncology Nurse & Patient Navigators Leadership Council since its inception in 2009 and speaks at their annual and regional conferences on nurse navigation issues. In 2012-2019, she co-chaired the annual AONN+ conferences as well as served on the teams for certification, metrics, and acuity. She is the AONN+ Local Navigation Network liaison. She serves on the editorial board of The Oncology Nurse-APN/PA (TON) and CONQUER and is the breast editor for the Journal of Oncology Navigation & Survivorship (JONS). She has also authored articles in JONS, Cancer, TON, Journal of Psychosocial Oncology, and CONQUER as well as authored chapters in the books Delivering Patient-Centered Care Across the Continuum, Oncology Nurse Navigation Case Studies, Team-Based Oncology Care, and Guide to Breast Care for Oncology Nurses. She also assisted in organizing the state navigation association—North Carolina Oncology Navigator Association.

She has been a member of the Oncology Nursing Society since 1983. She was a founding member of the Piedmont Triad Oncology Nurse Chapter in 1988 and has served in a leadership role since its inception through 2018. She was a participant at the inception of the Oncology Nursing Certified Breast Care Nurse examination and chaired the Oncology Nursing Certification Breast Care Committee 2010-2012. She holds certification as Certified Breast Care Nurse, Advanced Oncology Practice Nurse, Oncology Nurse Navigation Certification, and Honorary Oncology Nurse Navigation-Certified Generalist.

Ms Gentry travels nationally lecturing on the navigation concept. On the local level, she serves on the board of the local hospice and participates in the Derrick L. Davis Forsyth Regional Cancer Center Oncology Breast Advisory Committee.

Rose Gerber

Director, Patient Advocacy & Education, Community Oncology Alliance

Rose Gerber is Director, Patient Advocacy & Education, Community Oncology Alliance, Washington, DC, where she developed the current patient advocacy program and added an advocacy track to the annual conference to bring together physicians, administrators, and advocates. Previously, she has served as a consumer reviewer on the Congressionally Directed Medical Research Programs – Department of Defense Breast Cancer research panels.

She is a nationally recognized cancer advocate and survivor and has appeared on MSNBC to speak about cancer care, met with legislators in Washington, DC, on cancer policy issues, and developed cancer programs. She was recently honored as the National Breast Cancer Leader of the Year and has been keynote speaker for many national conferences. She has served for 5 years as a grant reviewer, speaker, and educator for Susan G. Komen and has also co-founded and managed a breast cancer mentoring program for Eastern Connecticut Hematology & Oncology.

Ms Gerber obtained a dual bachelor’s degree in public relations, advertising, and applied communication and psychology from New Mexico State University, Las Cruces.

Lisa Gill

Managing Director, Senior Analyst - Healthcare Technology and Distribution, JP Morgan Securities, LLC

Lisa Gill is Managing Director, Healthcare Technology and Distribution, JP Morgan, New York, NY, where she has been a leading member of the healthcare equity research team for 20 years. She is highly regarded for her in-depth analysis and management relationships.

She has been ranked #1 by Institutional Investor for the past 8 years and has consistently been ranked in the top 3 by Institutional Investor and external polls since 2005. She is a member of the Investment Bank Women’s Network and is a leading member of Women in Research, where she heads the mentoring committee.

Ms Gill is a certified public accountant and obtained her bachelor’s degree in business administration from Siena College, Loudonville, NY.

Gerry Gleeson, MBA



Brian Gockerman, MBA

Managing Director, Unlimited Systems

Brian Gockerman is Managing Director, Unlimited Systems, Cincinnati, OH. Unlimited Systems is a developer of the leading revenue cycle software platform for the oncology revenue cycle, the g4 Studio. In addition to creating workflow automation software used in independent practice settings as well as cancer service lines at hospitals and health systems, the company is also well- known for optimizing use of the Centricity billing system in cancer specialist installations across the United States.

Mr Gockerman’s company portfolio includes more than 275 cancer centers; more than 3100 oncologists; integration packages for every major oncology-specific clinical application; installations in 42 states and Puerto Rico; and clients ranging from solo practitioners to groups of more than 200 providers as well as those requiring institutional billing expertise.

He obtained his bachelor’s degree in industrial engineering from Stanford University, CA, and his master’s degree in health/healthcare administration and management from The Wharton School of the University of Pennsylvania, Philadelphia.

Rena Goins



Bob Gold

Chief Behavioral Technologist and CEO, GoMo Health

Bob Gold is Chief Behavioral Technologist and CEO GoMo Health, a division of Gold Group, Asbury Park, NJ. One of the world’s leading behavioral technologists with more than 20 years of applied research and development in the behavioral and cognitive science of human motivation, activation, and resiliency, Mr Gold focuses on recrafting clinical care plans into behaviorally based remote care coordination, transitions of care, and telehealth patient engagement protocols to achieve sustainable population health business models for health systems, health plans, pharmaceutical companies, and governments.

Prior to founding Gold Group, Mr Gold was President, Starpoint Solutions, where he designed and launched the first ever electronic 401(k) and stock options systems for major money center banks and financial institutions. He grew Starpoint Solutions from a start-up company to a company worth $80 million in 6 years.

Mr Gold received his bachelor’s degree in economics from Rutgers University, New Brunswick, and his master’s degree in computer science from Fairleigh Dickinson University, Teaneck, NJ.

Patricia Goldsmith

Chief Executive Officer, CancerCare

Patricia Goldsmith is Chief Executive Officer, CancerCare, New York, NY, where she oversees the vision and direction of the organization. She brings more than 20 years of nonprofit management and strategic planning experience to the role and has a proven track record of success in hospital and physician academic organizations, as well as nongovernmental healthcare organizations.

Prior to her current position, Ms Goldsmith was Executive Vice President and Chief Operating Officer, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, where she was responsible for the overall operations and provided oversight of the functions of many divisions within the NCCN, such as the NCCN Oncology Outcomes Database, the NCCN Oncology Research Program, and the US and Global Business Development. In 2013, Ms Goldsmith was chosen by US Representative Bill McCollum to join a panel of 100 thought leaders representing every stakeholder interest in healthcare, which focused on building consensus about what structural changes could be made in our nation’s healthcare delivery system to assure quality healthcare for future generations.

Ms Goldsmith has studied at Pennsylvania State University, University Park; the University of Missouri Bloch School of Business, Kansas City; and the Harvard School of Public Health, Boston, MA.

Russell Gollard, MD



Janet Gordils-Perez, DNP, RN, ANP-BC, AOCNP

Regional Vice President, Oncology Services, Summit Health Management

Janet Gordils-Perez is Regional Vice President, Oncology Services, Summit Health Management, Florham Park, NJ, where she is responsible for the integration of the expanding multidisciplinary service line while focusing on patient engagement and expansion of services, such as medical, surgical, radiation oncology, navigation services, infusion services, and research, throughout Northern New Jersey.

Prior to her current position, Dr Gordils-Perez was Chief Nursing Officer, Adult Nurse Practitioner, Rutgers Cancer Institute of New Jersey, New Brunswick, where she led orchestrating efforts to expand navigation programs across the Robert Wood Johnson Barnabas Health System by implementing and developing a clinical navigation program to increase patient satisfaction. Her expertise is redesigning clinical processes, increasing revenue opportunities, and implementing innovative programs to improve patient experience.

Dr Gordils-Perez obtained her bachelor’s degree in nursing from the College of New Rochelle, NY; her master’s degree in nursing from New York University; and her Doctor of Nursing Practice from Duke University, Durham, NC.

Scott Gottlieb, MD

Former Commissioner, US Food and Drug Administration

Scott Gottlieb served as the 23rd Commissioner of the US Food and Drug Administration (FDA) from May 2017 to April 2019. His work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. During his tenure as Commissioner, Dr Gottlieb oversaw the FDA’s historic and prolific advances in new policy in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.

Prior to his tenure as Commissioner, Dr Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and was a Senior Advisor to the Administrator of the Centers for Medicare & Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies.

Dr Gottlieb is widely published in leading medical journals and periodicals. He has held editorial positions on the British Medical Journal and the JAMA: The Journal of the American Medical Association. He has been named one of the “World’s 50 Greatest Leaders” in 2018 and 2019 by Fortune magazine; one of the “Most Influential Physician Executives and Leaders” by Modern Healthcare; and one of the “50 People Transforming Healthcare in 2018” by Time magazine.

Dr Gottlieb obtained his bachelor’s degree in economics from Wesleyan University, Middletown, CT, and his medical degree from the Icahn School of Medicine at Mount Sinai, New York, NY.

Niesha Griffith, RPh, MS, FASHP

Advising Partner, McGivney Global Advisors

Niesha Griffith is Advising Partner, McGivney Global Advisors, Wayne, PA, where she provides consulting services for the pharmaceutical industry and oncology practices. Prior to her current positions, Ms Griffith was Vice President, Oncology Services, West Virginia University, Morgantown, and Administrator, Oncology Pharmacy and Infusion Services, Arthur G. James Cancer Hospital, The Ohio State University, Columbus. Ms Griffith has served as Past President of the Hematology/Oncology Pharmacy Association; Past President of the Central Ohio Society of Health-System Pharmacists; and Past Chair of the Leadership Advisory Group of the American Society of Health-System Pharmacists. She has been successful in the development of clinical programs and services aimed at improving supportive care management of patients with cancer.

Ms Griffith earned her bachelor’s degree in pharmacy from West Virginia University and her master’s degree from The Ohio State University College of Pharmacy.

Gina Guinasso, JD

Senior Vice President, Industry Relations, Commercial & Medicare Formulary Contracting Strategy, OptumRx

Gina Guinasso is Senior Vice President, Industry Relations, Commercial & Medicare Formulary Contracting Strategy, OptumRx, Irvine, CA, where she is responsible for the day-to-day rebate negotiations for commercial, managed Medicaid, and Medicare Part D. Her team is also responsible for formulary strategy development and execution of manufacturer agreements for pharmacy and medical benefit products.

Prior to her current role, Ms Guinasso was Senior Director, Market Access, Takeda Oncology, Boston, MA; Senior Director, Managed Care, Cubist Pharmaceuticals, Lexington, MA; and Director, Managed Markets, Acorda Therapeutics, Seattle, WA.

Ms Guinasso received her bachelor’s degree in international business from Washington State University, Seattle, and her law degree from Seattle University.

Judith Haber, PhD, APRN, BC, FAAN



Mark Hagler

SVP, Head, Ophthalmics, Oncology & Long Term Care, Sun Pharma

Mark Hagler is a visionary, results-oriented leader with an impressive track record—over 20 years of US and global leadership experience within the biotech/pharmaceutical industry. He is currently leading the commercial Ophthalmics, Oncology, and Long-Term Care businesses at Sun Pharma.

Prior to Sun, he was Head of Oncology Marketing at Ipsen and was the architect of the highly successful US launch of lanreotide for gastrointestinal and pancreatic neuroendocrine tumors. At Novartis, he was responsible for the successful global launch of everolimus in ER+ breast cancer and as a Global New Products lead, advanced numerous phase 1/2 compounds into phase 3 registrational trials with planned indications, including ER+ and HER2+ breast cancer, recurrent ovarian, DLBCL, HCC, RCC, and gastric cancer. He is a member of the Board of Directors of the Ranbaxy Signature joint venture and a graduate of Johns Hopkins University and the US Naval Academy.

James Hamrick, MD, MPH

Senior Medical Director, Flatiron Health

James Hamrick is Senior Medical Director, Flatiron Health, New York, NY, where he is responsible for overseeing the clinical development of the OncoTrials and research software products as well as providing clinical insight into the development of new features in OncoEMR. Dr Hamrick also maintains a clinical practice part-time at Kaiser Permanente Georgia, Atlanta, where he previously served as Chief, Medical Oncology and Hematology.

Dr Hamrick serves as Board Member, Georgia Center for Oncology Research and Education; Executive Leadership Council, Atlanta Chapter, American Cancer Society; and Political Ambassador, The Southeast Permanente Medical Group.

Dr Hamrick received his medical degree from University of North Carolina, Chapel Hill School of Medicine, where he also received his master’s degree of public health in epidemiology. He is currently board certified in internal medicine, medical oncology, and hematology.

William Harwin, MD



Robert Hauser, PharmD, PhD

Vice President, Clinical Analytics, Cancer Treatment Centers of America

Robert Hauser is Vice President, Clinical Analytics, Cancer Treatment Centers of America (CTCA), Dallas, TX, where he is responsible for identifying, streamlining, analyzing, and utilizing all forms of clinical data to ensure that the highest quality care and outcomes are provided at all CTCA locations. In addition, he is responsible for developing and running the health economics and outcomes research line of business for CTCA.

Dr Hauser has more than 20 years of experience in health economic and strategy planning services related to clinical trial development, oncology registries, electronic medical record systems, informatics, and business development. He has led more than 20 research activities, has authored more than 10 peer-reviewed publications, served as guest editor, and has presented hundreds of times to audiences large and small.

He received his doctorate in clinical pharmacy, health economics, and administration from The University Texas at Austin, and obtained a doctoral degree in healthcare administration/management from The University of Texas Health San Antonio.

Tara Herington, RN

Vice President, Cardinal Health Specialty Solutions

Tara Herington is a seasoned biotechnology and operations executive with more than 20 years’ experience. She has successfully built organizations and patient support programs for small, mid-sized, and large pharmaceutical manufacturers. She enjoys working in concert with manufacturers to deliver outstanding patient engagement and brand success. With an eye on analytics and a passion for doing the right thing for patients, Tara strikes a balance to deliver programs that are patient-centered and results-oriented. Prior to her current role with Cardinal Health, she was responsible for leading pharmaceutical manufacturer patient support programs across multiple disease states. Although she enjoyed her time working on the client side of the table, she is now translating that experience to her current role. She also has experience in field reimbursement, training, payer strategy, and quality assurance. She maintains her RN licensure in the state of Texas.

Andrew Hertler, MD, FACP

Chief Medical Officer, New Century Health

Andrew Hertler, as the Chief Medical Officer of New Century Health, is responsible for the advancement of the company’s clinical quality initiatives, value-based strategies, and utilization management policies and operations. A board-certified oncologist who left clinical practice in 2014, he is a nationally recognized leader in oncology clinical practice. Dr Hertler is a member of several American Society of Clinical Oncology committees, including the Clinical Practice, Quality of Care, and Payment Reform committees.

Prior to joining New Century Health in 2014, he was Administrative Medical Director for Physician Practices at Maine General Medical Center and Medical Director of the Harold Alfond Center for Cancer Care in Augusta, ME. He is Past President of the Northern New England Clinical Oncology Society. Earlier in his career, Dr Hertler was Assistant Professor of Medicine in Hematology/Oncology at the Louisiana State University Medical School.

He received his medical degree from the University of Michigan and completed his residency in internal medicine at University of Michigan–affiliated hospitals. He later completed a Fellowship in Medical Oncology/Hematology at Duke University Medical Center. He received his bachelor’s degree in chemistry with highest honors from Dartmouth College.

Mark Hiatt, MD



Mitch Higashi

VP, Health Economics and Outcomes Research, Bristol-Myers Squibb

Mitch Higashi is Vice President of Health Economics and Outcomes Research at Bristol-Myers Squibb (BMS). Prior to joining BMS, he was Chief Economist for GE Healthcare, where he led global efforts in health economics, pricing, reimbursement, and health policy. He is a published author, including JAMA, and his work in molecular diagnostics has been featured in the Wall Street Journal and on National Public Radio. His team’s efforts to organize the GE Healthcare R&D portfolio based on cost, quality, and access metrics was featured in a Harvard Business School case study. He has served on the Board of Directors for the University of Washington Foundation and the ISPOR Health Science Policy Council. Dr Higashi is a graduate of the University of British Columbia and The Wharton School and he holds a PhD degree in health economics from the University of Washington.

Ross Hoffman, MD



Clifford Hudis, MD

Chief Executive Officer, American Society of Clinical Oncology

Cliff Hudis is Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as Chief Executive Officer of its Conquer Cancer Foundation and Chairman of the Board of Governors of ASCO’s CancerLinQ. Dr Hudis previously served in a variety of roles at ASCO, including as President during the Society’s 50th anniversary year (2013-2014). Before transitioning full-time to ASCO, he was Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities. As Chief Executive Officer of ASCO, Dr Hudis’ focus is on education, research, and promotion of the highest quality of care by the Society’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians.

Anne Ireland, MSN, RN, AOCN

Executive Director, Community Nursing Practice & Outreach, City of Hope National Medical Center

Anne Ireland has been an oncology nurse for more than 30 years. She is currently Executive Director, Community Nursing Practice & Outreach at the City of Hope National Medical Center in Duarte, CA. In addition, she was recently the Nursing Lead for the implementation of ConnectHope, which is City of Hope’s enterprise-wide electronic health record.

Prior to relocating to California, she was Director of Clinical Practice & Innovation for Nursing Services at the University of Vermont Medical Center (UVMC) in Burlington, VT, where she also served as the clinical architect for the implementation of their electronic health record. She was Director for Oncology Nursing at UVMC and held a variety of roles in the Vermont Cancer Center during her more than 20 years in Vermont.

Prior to moving to Vermont, she was an Oncology Nurse and a Clinical Nurse Specialist in Toronto, Ontario, at Sunnybrook Health Science Center.

She has been active in the Oncology Nursing Society (ONS) at the local and national levels and most recently has been elected to a 3-year term on the national ONS Board as Director at Large.

She received her BSN degree from the University of New Brunswick and her MSN from the University of Toronto.

Scott Jauch

Senior Director, Contract Strategy – Specialty, AstraZeneca Pharmaceuticals

Scott Jauch is Senior Director of Contract Strategy leading a team that implements outcomes-based contracts and innovative value strategies for AstraZeneca’s oncology, respiratory biologics, and future specialty products. At AstraZeneca, he held roles within the US Oncology, Market Access, Government Affairs, and Policy teams. Prior to AstraZeneca, he led government affairs and policy activities for Novartis Vaccines. He spent 4 years at Avalere Health, a Washington, DC, strategic advisory firm, where he advised clients across the healthcare spectrum about changes in the legislative/regulatory environment and emerging reimbursement models that pay for value over volume. Prior to Avalere, he negotiated pay-for-performance contracts with health plans on behalf of Partners HealthCare in Boston. He began his career in physician practice management working for physicians in academic and community settings, as well as advising members of the Massachusetts Medical Society and the American College of Physicians.

He received a bachelor’s degree in sociology from Case Western Reserve University and a master’s degree in healthcare management from Marymount University.

Kate Jeffers, PharmD, MHA, BCOP

Clinical Pharmacist, Memorial Hospital

Kate Jeffers is a Clinical Pharmacist, Health Memorial Hospital, Colorado Springs, where she is also the PGY1 Pharmacy Residency Program Director and the PGY2 Oncology Residency Program Director, Pre-Candidate Status.

Active in national organizations, Dr Jeffers is currently a member of the Board of Directors for the Advanced Practitioner Society for Hematology and Oncology; Chair, External/Professional Affairs Committee, Hematology/Oncology Pharmacy Association; and Chair, Academy of Health-System Pharmacists, Colorado Pharmacists Society. She is also an active reviewer for peer-reviewed journals, such as the Journal of Oncology Practice, the Journal of the Advanced Practitioner in Oncology, and the American Journal of Health-System Pharmacy.

Dr Jeffers obtained her bachelor’s degree in biology with a minor in chemistry, cum laude, from Virginia Tech, Blacksburg; her doctorate degree from the University of Maryland School of Pharmacy, Baltimore; and completed her PGY1 pharmacy and PGY2 oncology residencies at The Johns Hopkins Hospital, Baltimore, MD. In addition, she obtained her master’s degree in health administration from Capella University.

Danelle Johnston, MSN, RN, HON-ONN-CG, OCN

Chief Nursing Officer, Sr. Director of Planning and Initiatives, The Lynx Group

Danelle Johnston is Chief Nursing Officer, Senior Director of Planning and Initiatives for The Lynx Group. In this role, she oversees the strategic and operational responsibilities of staff, programs, and expansion of the Academy of Oncology Nurse & Patient Navigators (AONN+) as well as the execution of its mission. She is instrumental in supporting the many committee activities within AONN+, exploring and nurturing partnerships with other organizations in clinical and oncology arenas, and providing key clinical and professional insight that will help AONN+ enhance its sponsorships and services.

With more than 24 years of experience holding a variety of positions and a diverse and progressive oncology nursing background, she is recognized as a national leader in oncology nurse navigation and in innovative community outreach and education focused on improving clinical care coordination and supporting the growth of others in the profession. Providing the most recent evidence of this was her appointment to the Biden Cancer Initiative Advisory Committee and Chair, Biden Patient Navigation Working Group.

As a longtime AONN+ member, she serves on the Academy’s Leadership Council and co-chairs its Quality Metrics Task Force. Her leadership has helped the task force to identify and document 35 standardized evidence-based metrics for navigation that concentrate on return on investment, patient experience, and clinical outcomes. For her efforts, AONN+ recognized her with its “Exceptional Research in Navigation Award.”

She earned a bachelor’s degree from Azusa Pacific University and a master’s degree in nursing, with an emphasis on leadership and management, from Western Governors University. She is a member of the American Cancer Society’s National Navigation Roundtable: Evidence-Based Promising Practices Committee.

Ben Jones



Kristi Jones



Robert Jones

Managing Director, Global Investment Research, Goldman Sachs

Robert Jones is Managing Director for the Healthcare Supply Chain and Information Technology sectors in Global Investment Research. He joined Goldman Sachs as an associate in 2008 and was named Vice President in 2009 and Managing Director in 2017.

Prior to joining the firm, he worked at UBS Securities LLC as Associate Analyst in the Generic Pharma Manufacturers, PBMs, Distributors, and Labs Group. Earlier in his career, he worked at Johnson & Johnson Company as Senior Analyst in the Strategic Planning and Business Analytics Group. He earned his bachelor’s degree in finance from Lehigh University in 1999.

Mostafa Kamal



Deborah Kamin, RN, PhD



Tesh Khullar, MBA

Senior Vice President, Provider Solutions, Flatiron Health

Tesh Khullar is Senior Vice President, Provider Solutions, Flatiron Health, where he oversees all provider-focused activities across sales, account management, support, and implementation. His team focuses on providing enhanced support to cancer care providers through the OncoCloud software suite.

Prior to his current position, Mr Khullar was National Vice President, Oncology Sales & Account Management, McKesson Specialty Health, Mission Viejo, CA; and a variety of roles for Oncology Therapeutics Network, from business development to helping form one of the leading oncology-specific group purchasing organizations (Onmark) in 2005.

Mr Khullar received a bachelor’s degree in American history with a minor in computer science and engineering, University of California, San Diego, and a master’s degree in business administration, University of San Francisco School of Management.

Ira Klein, MD, MBA, FACP



Michael Kleinrock

Research Director, IQVIA Institute for Human Data Science

Michael Kleinrock serves as Research Director for the IQVIA Institute, setting the research agenda for the Institute, leading the development of reports and projects focused on the current and future roles of biopharmaceuticals in healthcare in the United States and globally. He joined the company in 1999 and has held roles in consulting, service, and marketing and assumed his current role in 2011. He holds a bachelor’s degree in history and political science from the University of Essex, Colchester, United Kingdom, and a master’s degree in journalism and radio production from Goldsmiths College, University of London, United Kingdom.

Chrys Kokino, MBA

Head Global Biologics & Insulins Commercial, Mylan

Chrys Kokino has been engaged in the world of specialty drugs for more than 31 years. He has held various leadership roles within the pharma and biotech world and is currently Global Commercial Head for Biologics and Insulins at Mylan. His broad base of experience spans multiple therapeutic areas such as oncology, immunology, endocrinology, and nephrology. He has launched and commercialized multiple specialty products in the United States and worldwide, including Europe, Asia, Africa, and the Middle East, with products ranging in value of more than $1 billion. He has represented top-tier pharma and biotech companies such as Bristol-Myers Squibb, Amgen, and Roche. In the past 13 years, he has had a singular focus and passion on launching and commercializing biosimilars worldwide, first with Sandoz and now with Mylan where the team successfully launched the world’s first biosimilar (trastuzumab), the first biosimilar (pegfilgrastim) in the United States, and 2 recent European biosimilar launches with adalimumab and insulin glargine.

Michael Kolodziej, MD

Vice President, Chief Innovation Officer, ADVI Health

Michael Kolodziej is Vice President and Chief Innovation Officer, ADVI Health. He attended college and medical school at Washington University in St. Louis, where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, he joined the faculty at the University of Oklahoma School of Medicine, where he was an associate professor. He joined New York Oncology in 1998 and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy & Therapeutics Committee, on the Executive Committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He joined Aetna in January 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s oncology delivery reform pilots and was the architect of the Aetna Oncology Medical Home program. He was also active in Aetna’s pharmacy policy, condition analysis, and genetics subcommittees. Dr Kolodziej joined Flatiron Health in July 2016 as National Medical Director, Managed Care Strategy, where he applied the core tech and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. He joined ADVI in October 2017. He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.

Michele Korfin

Chief Operating Officer, TYME Technologies

Michele Korfin is Chief Operating Officer, TYME Technologies, New York, NY, a clinical stage biotechnology company developing novel cancer therapeutics intended to be effective across a broad range of tumor types and have low toxicity profiles. She has more than 20 years of experience in oncology, focused on product launches, clinical development, oncology market strategy, commercial sales, market access, and government affairs.

Prior to her current position, she was Vice President, Market Access, Kite Pharma, Los Angeles, CA, where she oversaw the market access strategy, including payer relations, reimbursement, and government affairs for Yescarta, the first approved CAR T-cell therapy in lymphoma. She also established the Chain of Identity approach for the Kite CAR T-cell therapy and led the Kite Konnect team.

Ms Korfin obtained her bachelor’s degree in pharmacy from Rutgers University, New Brunswick, NJ, and her master’s degree in business administration from Harvard Business School, Boston, MA.

Scott Kornhauser

Chief Executive Officer, President, KlearTrust

Scott Kornhauser is Chief Executive Officer, President, KlearTrust, Chicago, IL. Prior to his current position, Mr Kornhauser was Senior Vice President, Customer Success and Operations, Apervita, Chicago; and Chief Executive Officer, Park Street Solutions Company, Chicago, IL.

Mr Kornhauser has more than 30 years of healthcare information technology and operating experience, which has led him to lead multiple successful healthcare technology ventures, delivering numerous multimillion-dollar, complex, enterprise healthcare technology implementations. His experience includes innovative product development and delivery of large-scale enterprise payer, pharmacy management, claims processing, benefits administration, and analytics solutions.

Mr Kornhauser received his bachelor’s degree from State University of New York, New Paltz.

Neal Lambert

Senior Director, Team Lead Pricing Strategy, US Biosimilars, Pfizer Oncology

Neal Lambert is Senior Director, Pricing and Value Strategy, for the Pfizer US Biosimilars Portfolio. He has more than 20 years of experience in brand and value-based access marketing. Mr Lambert has led successful launches at Pfizer in both the US and Japanese markets as well as at Amgen in the US oncology market in both marketing and sales leadership roles. He is a graduate of the University of Pennsylvania and holds a master’s degree in international business studies from the University of South Carolina.

Kathryn Lang, MD

VP, Outcomes and Evidence, Guardant Health

Kathryn Lang is physician and epidemiologist who has worked in disease registries, observational clinical research, and real-world data for the past 10 years. Trained in the United Kingdom as a hemato-oncologist, Dr Lang transitioned to industry in her role with Pfizer in 2016, eventually leading the global data science group in New York City with responsibility to develop regulatory-grade real-world evidence and to apply advanced data science techniques to traditional clinical trial design, execution, and recruitment. In her current role as Vice President of Outcomes and Evidence at Guardant Health, she has broad experience, including observational clinical trials and health economics as well as data-driven engagements with biopharmaceuticals continuing her work in modernizing access to informative real-world data.

Rick Lanman, MD



Thomas LeBlanc, MD

Department of Medicine, Duke University School of Medicine

Thomas LeBlanc is a clinical hematologic malignancies specialist, palliative care physician, and patient experience researcher. His clinical practice focuses on the care of patients with myeloid malignancies and acute leukemias, including acute myeloid leukemia (AML), acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, and related diseases. He serves on the National Comprehensive Cancer Network guideline panel for AML. His research uses both quantitative and qualitative methods to further our understanding of the patient experience of living with (and being treated for) cancers of the blood, aimed at informing interventions to improve those experiences. His recent efforts have focused on fostering a better understanding of issues faced by patients with AML, including those related to symptom burden, quality of life, distress, prognostic understanding, and treatment decision-making. His long-term research and career goal is to develop and test innovative models for integrating palliative care as a standard part of blood cancer care, far upstream from the end-of-life phase, and to improve the overall patient experience of cancer. His work in palliative care for patients with blood cancers has led to his recognition as an “Inspirational Leader Under 40” by the American Academy of Hospice and Palliative Medicine (AAHPM), an invitation to Chair an Education Program session on palliative care in hematologic malignancies at the 2015 American Society of Hematology meeting, the receipt of a Cambia Foundation Sojourns Scholars Leadership Award, induction as a Fellow of the AAHPM in 2016, and receipt of the international “Clinical Impact Award” from the European Association for Palliative Care in 2018. Dr LeBlanc’s research has been funded by the National Institutes of Health, the National Palliative Care Research Center, the Cambia Health Foundation, and the American Cancer Society, along with various industry partners, and he has published more than 100 peer-reviewed MEDLINE-indexed articles, along with several chapters in prominent textbooks in oncology and palliative medicine, and served as a keynote speaker at several national and international meetings.

Jenny Lee, PharmD, MBA, MPH

Consultant, Global Pricing and Market Access, ICON

Jenny Lee is Consultant, Global Pricing and Market Access, ICON, New York, NY, where she manages a diverse portfolio of projects in areas around pricing and market access, including primary and secondary research, value communications, and payer engagements. Prior to her current position, Ms Lee was Associate Consultant, Simon-Kucher & Partners, Singapore; Research Assistant, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Associate, Clinical Quality Assurance, Samsung Bioepis, Incheon, South Korea.

She has expertise in shaping and executing global and/or local access strategies, pricing research, health technology assessment, and evidence optimization, from her involvement in various therapeutic areas, including infectious diseases, oncology, rheumatology, and endocrinology.

Ms Lee obtained her master’s degree in business administration and master’s degree in public health from Johns Hopkins University, and her doctorate in pharmacy from Seoul National University, South Korea.

Rick Lee, MBA, PhD



Pierre Leurent

CEO, Voluntis

Pierre Leurent, Chief Executive Officer and Founder of Voluntis, has 20 years of experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with digital therapeutics. Its clinically validated, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team.

Prior to starting Voluntis, he worked at GE Medical Systems, where he took part in the development of medical imaging software. He also had several positions at HealthCenter Internet Services, a San Francisco–based vendor of electronic medical record solutions.

He is a founding member of the Digital Therapeutics Alliance, of which he serves as first Chairman.

Mr Leurent also co-chairs the Digital Therapeutics Task Force of the Personal Connected Health Alliance (member of HIMSS), and he is Chairman of the eHealth France Alliance.

He is a graduate of the Ecole Centrale Paris Engineering School.

Jonathon Levitt, JD

Co-Founding Partner, Frier Levitt, LLC

Jonathan Levitt co-founded the boutique healthcare law firm of Frier Levitt, LLC in 2000. Frier Levitt enjoys a national foothold in life sciences and healthcare. Beginning with a 2003 nationwide class action of independent pharmacies, he began his journey to both understand all aspects of the drug space and develop skills relevant to multiple stakeholders. Frier Levitt has grown to more than 35 healthcare-focused attorneys, including clinician attorneys, with offices in New York City and Pine Book, NJ.

At Frier Levitt, he has dedicated his practice to representing pharmacies, physician-dispensers, national provider associations, manufacturers, wholesalers, and plan sponsors. He has an established track record of challenging abusive practices of pharmacy benefit managers and speaks at life sciences conferences across the country to share his firm’s specialized knowledge. He is the author of the LinkedIn Group “Hot Topics in Pharmacy Law” and has been published in internationally circulated publications. He commits himself to pro bono and public service assignments.

Brian Leyland-Jones, BSc, MBBS, PhD, FRACP, FRCPC

Chief Medical Officer, National Foundation for Cancer Research

Brian Leyland-Jones is Chief Medical Officer, National Foundation for Cancer Research. Dr Leyland-Jones is also Chief Medical Officer, OTraces, Rockville, MD, and Chief Medical Officer, N of 1 Mission, Concord, MA. He also serves as Director Emeritus for the Worldwide Innovative Networking in Personalized Cancer Medicine Consortium.

Prior to his current role, Dr Leyland-Jones led the Genomics Medicine Program at the Avera Cancer Institute, Sioux Falls, SD, and was the Vice President of Molecular and Experimental Medicine from 2014-2019. Prior to this, Dr Leyland-Jones was Founding Chair, Oncology, and Director, McGill University Comprehensive Cancer Centre, Montreal, Canada.

He received biochemistry, medical, and doctoral degrees from the University of London, UK, and completed a clinical pharmacology fellowship at Cornell University, Ithaca, NY, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Bob Li, MD, MPH

Medical Oncologist, Memorial Sloan Kettering Cancer Center

Bob Li is an attending medical oncologist at the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY. Dr Li is also MSKCC’s designated Physician Ambassador to China and Asia-Pacific. In this role, he represents MSKCC on an official level in coordinating international patient care, research, and education programs with China and the Asia-Pacific region.

Dr Li completed his medical degree at the University of New South Wales in Sydney, Australia, and postgraduate training at the Royal Australasian College of Physicians and University of Sydney. He has completed medical oncology fellowships at Royal North Shore Hospital and MSKCC. As principal investigator and physician-scientist, Dr Li leads numerous phase 1 and 2 basket trials of new cancer medicines targeting HER2 and the MAPK pathways. His translational research in the HER2 oncogene has led to the completion of the first positive clinical trial in patients with HER2-mutant lung cancers, which has already changed the 2018 NCCN Clinical Practice Guidelines for non–small-cell lung cancer. Dr Li is also Co-Director of the MSKCC Thoracic Liquid Biopsy Program investigating the use of plasma circulating tumor DNA sequencing technology to optimize precision therapy. His team’s research efforts have led to regulatory approvals of liquid biopsy assays ctDx Lung and MSK-ACCESS by the New York State Department of Health.

He has received awards from the American Society of Clinical Oncology and the American Association for Cancer Research for his research and has numerous scientific articles in prestigious journals such as Nature, Nature Medicine, Cancer Discovery, and Journal of Clinical Oncology. As a physician-scientist, his career mission is to bring hope to patients by accelerating therapeutic advances in the war on cancer.

Douglas Long, MBA

Vice President, Industry Relations, IQVIA

Douglas Long is Vice President, Industry Relations, IQVIA (formerly Quintiles IMS), Ponte Vedra Beach, FL, where, throughout his 30-year tenure, he helped secure data for all existing and new databases supported by IQVIA; manage supplier, manufacturer, and association relationships; and develop information for data partners. Mr Long has considerable experience with the changing US and global healthcare marketplace and pharmaceutical distribution.

He has been honored with prestigious awards, including the National Association of Chain Drug Stores’ Harold W. Pratt Award for his contribution to the promotion, recognition, and improvement of the practice of pharmacy within the chain drug industry. He is also the recipient of the 2016 International Federation of Pharmaceutical Wholesalers’ Leadership Award.

Mr Long received a bachelor’s degree from DePauw University, Greencastle, IN, and a master’s degree in management from Fairleigh Dickinson University, Teaneck, NJ.

Roger Longman



JoAnn Lovins, MS, RN



Bryan Loy, MD, MBA

Physician Lead, Oncology, Laboratory, and Personalized Medicine, Health Care Services – Humana

Bryan Loy attended the University of Louisville, where he earned board certification in anatomic and clinical pathology as well as hematology. He co-chairs the Louisville Health Advisory Board in pursuit of improving the health of the community and serves as a board member for Humana Kentucky’s Bold Goal initiative. He leads Humana’s cancer initiatives and Humana’s Laboratory and Personalized Medicine initiatives. He also serves as a clinical laboratory advisor for the Centers for Medicare & Medicaid Services. Dr Loy has served in clinical practice as well as industry roles. He has extensive experience in administrative roles, including medical director for a third-party administrator, medical director for a Medicare A and Medicare B contractor, and, in his current roles for Humana, a commercial and Medicare health plan. Dr Loy has served on several steering committees and advisory boards, including National Quality Forum-Cancer Committee, American Cancer Society, National Comprehensive Cancer Network, and the National Business Group on Health. Locally, he co-chairs the Louisville Health Advisory Board in pursuit of improving the health of this great community. In his many roles, his objectives remain to promote quality and provide members with support to achieve their best health and receive the best outcomes from their healthcare delivery experience.

Aaron Lyss, MBA

Director, Strategy & Business Development, Tennessee Oncology

Aaron Lyss is Director of Strategy and Business Development for Tennessee Oncology, where he leads a variety of initiatives related to the integration of quality improvement and risk-sharing payment models, including CMMI’s Oncology Care Model and similar commercial payer programs.

He formerly worked in healthcare policy in the Washington, DC, area and earned his MBA with a specialization in healthcare at Vanderbilt University’s Owen Graduate School of Management. He is also a cancer survivor who has been in remission since July 2009.

He presents frequently to oncology stakeholders on topics related to the alignment of healthcare finance, operations, and strategic partnerships for success in the value-based payment landscape.

Ross Maclean, MD, PhD, MBA

Senior Vice President and Head, Medical Affairs, Precision Health Economics

Ross Maclean is Senior Vice President and Head, Medical Affairs, Precision Health Economics, Princeton, NJ, where he is responsible for medical support for the company’s health policy and economic research. He has more than 24 years of experience in health services and outcomes research, health economics, health system design, health policy, and market access in the United States and worldwide.

Prior to his current position, Dr Maclean was Chief Operating Officer, Precision Health Economics, Los Angeles, CA, and held many executive positions at Bristol-Myers Squibb, Plainsboro, NJ, including Vice President, Cardiovascular and Diabetes, US Medical; Vice President, Health Services, Global Medical; and Executive Director, Health Economics and Outcomes Research.

Dr Maclean received his medical degree, doctor of philosophy degree, and master’s degree in business administration from the University of Aberdeen, Scotland.

Gregory MacMichael, PhD

President and Founder, CMC BioServices, LLC

Gregory MacMichael is President and Founder, CMC BioServices, LLC, Rockaway, NJ. He is an experienced biopharmaceutical executive with more than 25 years of experience in the development and manufacturing of therapeutic proteins, vaccines, and cell and gene therapies. Prior to his current role, Dr MacMichael was Senior Vice President, Technical Operations, Axovant Gene Therapies, New York; Senior Vice President, Development and Manufacturing, NantKwest Therapeutics, Culver City, CA; and Global Head, Biologics Process Research and Development, Novartis Corporation, Basel, Switzerland.

He specializes in drug product development, optimization of capacity and capabilities to maximize output, CMC regulatory applications, and facility design and validation.

Dr MacMichael received his bachelor’s degree in microbiology from Pennsylvania State University, University Park; his master’s degree in microbiology/biochemistry from North Carolina State University, Raleigh; and his Doctor of Philosophy degree in microbiology/biochemistry from Mississippi State University, Starkville.

Ash Malik, MBA

President, Life Sciences Division, Integra Connect

Ash Malik is President, Life Sciences Division at Integra Connect. Prior to Integra Connect, he was a partner at the Strategy Group in PricewaterhouseCoopers, where he served clients primarily in oncology and precision medicine on opportunities related to growth, product commercialization, and enterprise-wide strategy design. In addition, he served in varying leadership roles at Merck & Co, where he participated in developing its US and global scientific strategy for metabolic diseases as well as international commercial operation requirements for biosimilars. Prior to Merck & Co, he was with French multinational BioMérieux, heading its divisional strategy to introduce molecular and genomics products in the US and European markets. Mr Malik holds a master’s degree in biochemical engineering from Duke University and a master’s degree in business administration from the Kenan-Flagler Institute at University of North Carolina, Chapel Hill.

Myla Maloney, MBA, BCMAS

VP, Strategic Accounts, Premier, Inc.

Myla Maloney is Vice President of Strategic Accounts for Premier, Inc. with 17 years of experience in strategic account management, healthcare sales, marketing, customer segment strategy, sales leadership, and pharmaceuticals. Ms Maloney supports Premier’s mission to transform healthcare by leading the Premier Life Sciences Business Development Group’s efforts to collaborate with life science organizations on population health improvement initiatives to improve the quality of patient care. Prior to this position, she was Vice President of Strategic Supplier Engagement for Premier, where she worked with biopharmaceutical and IT organizations. She received her bachelor’s degree in business administration and her MBA from East Carolina University.

Michelle Martin

VP, Employee Engagement, CBS Corporation

Michelle Martin is a human resources executive with an extensive background in supporting the health and well-being of employees, their families, and the community. She joined CBS Corporation in 2006 as Director of Health & Welfare Benefits. Holding several positions since joining CBS, she is now Vice President, Employee Engagement. She is responsible for employee health and well-being, including the development and strategy of the CBS Corporate Wellness programs, workplace benefits and policies, and employee and community engagement. She leads with a uniquely creative and multifaceted approach in engaging a large, diverse, and geographically dispersed employee population. Her goal is to achieve accessibility for employees by designing and implementing programs and policies to help them attain optimal health and live their best lives.

She is a Certified Employee Benefits Specialist with a certification in Global Benefits Management. She holds an MBA from Adelphi University and is an active member of the community. Ms Martin is Vice Chair of the Board of Directors for the Northeast Business Group on Health and is on the Board of Directors of The Leapfrog Group.

Rusty Massey



Ali McBride, PharmD, MBA



Mike McCarthy



Stacey McCullough, PharmD

Senior Vice President, Pharmacy, Tennessee Oncology

Stacey McCullough is Senior Vice President, Pharmacy, Tennessee Oncology, Nashville, TN, where she is responsible for leading and implementing pharmacy practice for Park Pharmacy, the in-practice specialty accredited URAC and Accreditation Commission for Health Care with Oncology Distinction.

Dr McCullough is also Director, Park Pharmacy, Tennessee Oncology, where she is responsible for all aspects of the pharmacy operations for a large community-based oncology practice. She oversees pharmacy contracting and group purchasing organization relationships; establish and standardize pharmacy practices; develop supportive care algorithms; and develop policies and procedures to ensure URAC specialty pharmacy accreditation.

Dr McCullough obtained her bachelor’s degree and doctorate degree from Auburn University, AL, and completed her residency at the University of Tennessee Medical Center, Knoxville.

Bob McDonough, MD



William McGivney, PhD



Sean McGowan, MBA

Senior Director, Biosimilars, AmerisourceBergen

Sean McGowan is Senior Director, Biosimilars, AmerisourceBergen, Conshohocken, PA, and is responsible for leading strategy and business development initiatives for the biosimilar product category. Mr McGowan has partnerships with biosimilar manufacturers in the precommercial, launch, and postlaunch phases to ensure the successful launch and growth of the products.

Prior to his current position, he was Senior Manager, Branded and Specialty Rx Contracts, AmerisourceBergen, Philadelphia, PA; Leader, Managed Markets Insight, AstraZeneca, Wilmington, DE; and Manager, Employer Partnerships, Accolade, Plymouth Meeting, PA. He has more than 10 years of experience in the healthcare industry, including the pharmaceutical, specialty pharmaceutical, and patient services areas.

Mr McGowan received his bachelor’s degree in American studies from Dickinson College, Carlisle, PA, and his master’s degree in business administration from the Fox School of Business, Temple University, Philadelphia.

Annastasiah Mhaka, PhD



Robert Miller, MD, FACP, FASCO

Medical Director, CancerLinQ, American Society of Clinical Oncology

Robert Miller is a medical oncologist and informaticist who serves as Medical Director, CancerLinQ, a health technology platform for oncology developed by the American Society of Clinical Oncology (ASCO). He provides scientific and clinical leadership for all aspects of CancerLinQ’s strategic plan and operations. He serves as primary staff support for the CancerLinQ physician committees, and he represents ASCO and CancerLinQ in numerous external collaborations to promote cancer data-sharing, interoperability, and standards, including the Minimal Common Oncology Data Elements (mCODE) initiative. Previously, he was ASCO Vice President for Quality and Guidelines, responsible for clinical practice guidelines, performance measurement, the Quality Oncology Practice Initiative, and quality informatics. From 2009 to 2014, he served as Oncology Medical Information Officer at the Kimmel Comprehensive Cancer Center at Johns Hopkins and specialized in the care of patients with breast cancer. His additional professional experience included the community practice of oncology in California, where he was president of the Sacramento Center for Hematology and Medical Oncology, and hospice medical director.

He is a graduate of the Medical College of Virginia, now Virginia Commonwealth University. He served a residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at Stanford University. He also received a graduate certificate in biomedical informatics at Oregon Health and Science University. He is board certified in internal medicine, medical oncology, and clinical informatics.

Michael Mong, PharmD

Director, Specialty Pharmacy Development, Walgreens

In his role as Director of Specialty Pharmacy Development at Walgreens, he collaborates with pharmaceutical manufacturers to craft strategies to bring products to market and provides support through implementation and launch.

Prior to moving into an account management role, he held several leadership positions at Walgreens Specialty Pharmacy, including supervising home infusion services, hemophilia, fertility, and limited distribution therapy–focused teams. In 2017, he assisted in creating and leading the first oncology therapy–focused team within Walgreens Specialty Pharmacy—a team dedicated to creating partnerships in the oncology space and offering personalized care to patients. Preceding his time in specialty pharmacy, he spent 5 years as a pharmacy manager with Rite Aid pharmacy, assisting with several district initiatives and vaccine administration services.

He received his doctorate in pharmacy from Duquesne University School of Pharmacy.

John Morrone, JD

Partner, Frier Levitt, LLC

John Morrone is a partner at Frier Levitt, LLC, and focuses his practice on transactional and regulatory healthcare law. Mr Morrone represents a broad panoply of clients from physicians to hospitals to pharmacies and drug manufacturers. He advises clients on matters involving anti-kickback, Stark, HIPAA, FDA, and DEA laws and rules and state licensing matters. He also represents clients in civil matters before the Department of Justice and the Office of the Inspector General, settling dozens of matters during his career. He also structures arrangements among referral sources and providers to ensure compliance with applicable laws and regulations.

Mr Morrone received his juris doctorate degree from Seton Hall Law School, graduating cum laude with a concentration in healthcare law. He also holds a Master of Business Administration from Baruch College/Mount Sinai Medical School in hospital and healthcare administration, as well as other degrees from New York University and the University of the State of New York.

Prior to joining Frier Levitt, LLC, he spent more than 20 years as a senior healthcare executive, holding positions with academic medical centers, and private and publicly traded physician practice management companies, and healthcare consulting groups. During his tenure as an executive at Maimonides Medical Center, he orchestrated the development of the premier cardiac catheterization and cardiac surgery programs in New York City.

Mr Morrone writes and speaks extensively on healthcare legal matters and is often interviewed and quoted by news outlets on healthcare topics. Most recently he was quoted in Bloomberg Business.

Raymond Muller, MS, RPh, FASHP

Associate Director, Pharmacy Services, Memorial Sloan Kettering Cancer Center

Raymond Muller is Associate Director of Pharmacy Services at Memorial Sloan Kettering Cancer Center in New York City with an operational annual budget of more than $1 billion. His responsibilities include being one of the senior members of the leadership team comprised of a 520-member Pharmacy Division. He leads the pharmacy’s drug policy management programs; training and education; and medication quality and safety programs. He is an active participant of the center’s Pharmacy & Therapeutics and the Hospital Quality Assessment & Improvement committees. He directs the pharmacy’s medication-use safety residency program and serves as Head of Research Pharmacy, funded by the National Cancer Institute. He has delivered more than 300 presentations at local, regional, and national educational programs. His numerous publications have appeared in the British Medical Journal, American Journal of Health-System Pharmacy, and the Journal of Clinical Oncology.

Brenda Nevidjon, MSN, RN, FAAN



Lee Newcomer, MD



Jeremy Nobel, MD, MPH

Founder, The UnLonely Project; Faculty, Harvard Medical School

Dr Nobel is a medical doctor, public health practitioner, and innovator who designs, implements, and evaluates healthcare management, digital therapeutic, and patient/consumer engagement systems. In addition to his academic teaching and research, Dr Nobel works in consultation with employers, major health plans, Taft-Hartley trusts, medical device and pharmaceutical companies, early-stage ventures, nonprofit organizations, and foundations in the design, implementation, and evaluation of effective healthcare management programs. In addition, he served as Medical Director at the Northeast Business Group on Health (NEBGH) for 8 years (2010-2018), where he founded and ran the NEBGH Solutions Center.

Also active in the field of medical humanities, Dr Nobel is president of the 501(c)(3) nonprofit Foundation for Art & Healing ( and founder of its signature initiative the UnLonely Project (, the leading nonprofit effort focused exclusively on addressing loneliness and social isolation. Dr Nobel is a published poet and has also received several awards for his poetry, including the Bain-Swiggett Prize from Princeton University and the American Academy of Poets Prize from the University of Pennsylvania.

Dr Nobel is a lecturer in the Department of Global Health and Social Medicine at Harvard Medical School (HMS) and serves on the faculty for the HMS Center for Primary Care. He is board certified in both internal medicine and preventive medicine, with dual master’s degrees in public health and epidemiology from the Harvard T.H. Chan School of Public Health. He graduated magna cum laude from Princeton University.

Kimberly Noonan, PhD, MPH

EVP, Founder & Chief Scientific Officer, WindMIL Therapeutics

Kimberly Noonan is a scientific co-founder of WindMIL along with Ivan Borrello, MD. Together, Drs Borrello and Noonan pioneered the use of marrow infiltrating lymphocytes (MILs) for the treatment of cancer. Dr Noonan received her bachelor’s degree in microbiology and PhD in immunology from the University of Pittsburgh. She also holds an MPH from Johns Hopkins University. Dr Noonan has published many peer-reviewed papers, review articles, and book chapters, and holds several patents. She joined the faculty of Johns Hopkins University in 2004 and maintains an adjunct faculty appointment. Currently, she is the Executive Vice President and Chief Scientific Officer at WindMIL Therapeutics.

Andrew Norden, MD, MPH, MBA

EVP, Founder & Chief Scientific Officer, WindMIL Therapeutics

Kimberly Noonan is a scientific co-founder of WindMIL along with Ivan Borrello, MD. Together, Drs Borrello and Noonan pioneered the use of marrow infiltrating lymphocytes (MILs) for the treatment of cancer. Dr Noonan received her bachelor’s degree in microbiology and PhD in immunology from the University of Pittsburgh. She also holds an MPH from Johns Hopkins University. Dr Noonan has published many peer-reviewed papers, review articles, and book chapters, and holds several patents. She joined the faculty of Johns Hopkins University in 2004 and maintains an adjunct faculty appointment. Currently, she is the Executive Vice President and Chief Scientific Officer at WindMIL Therapeutics.

John O’Brien, PharmD, MPH

Former Senior Advisor to Secretary, Drug Pricing Reform, of US Department of Health & Human Services

John O’Brien served as Senior Advisor to the Secretary at the US Department of Health & Human Services (HHS), where he led policy development on multiple administration priorities, including the drafting and execution of the President’s drug pricing blueprint. He also served as Deputy Assistant Secretary for Health Policy, and a key advisor to the Secretary for health policy research, development, and analysis related to Medicare, Medicaid, and private health insurance.

Prior to joining HHS, Dr O’Brien held senior policy positions in the life sciences and managed care industries, was a career official at the Centers for Medicare & Medicaid Services during the Obama administration, and served as a health policy fellow in the US Senate. He also holds several academic appointments and is passionate about mentoring the next generation of health policy leaders.

He has a master’s degree in public health from the Johns Hopkins Bloomberg School of Public Health, a doctor of pharmacy degree from Nova Southeastern University, and studied pharmacy and public policy at the University of Florida.


President/Director of Research, The Center for Cancer and Blood Disorders

Ray Page is President at The Center for Cancer and Blood Disorders, in Fort Worth, TX, and has practiced medical oncology for 22 years. Dr Page has been at the forefront of community oncology practice transformation towards value-based care, participating in a variety of payment reform models and development of pathway systems. His practice is currently exploring AI tools for risk stratification of cancer patients.

As Director of Research, he has been the principal investigator of more than 200 clinical trials and is well- published on a variety of cancer-related topics. He has a particular interest in healthcare policy and was recently acknowledged as the 2018 American Society of Clinical Oncology (ASCO) Advocate of the Year.

Dr Page actively serves ASCO, just completing role of Chair of the Clinical Practice Committee, Nominating Committee, Government Relations Committee, ASCO Delegate to the AMA House of Delegates, and State Affiliate Council past chair. He has contributed to the publication of several ASCO Policy statements.

Gary Palmer, MD, JD, MBA, MPH

Chief Medical Officer, Tempus, Inc.

Gary Palmer is Chief Medical Officer, Tempus, Inc., Chicago, IL, where he is responsible for leading clinical activities and supporting external collaborations and strategic partnerships. Prior to his current role, Dr Palmer was President and Chief Medical Officer, GPS Cancer Division, NantHealth, Culver City, CA; and Vice President, Medical Affairs, Genomic Health, Redwood City, CA, where he directed the medical aspects of the Oncotype DX Breast Cancer Assay.

Dr Palmer has been a medical oncologist in academic and community settings. He was Director, Medical Breast Service, University of California, Davis; Chief, Medical Oncology, Mercy Health System, Sacramento, CA; and Adjunct Faculty, University of California Davis, Graduate School of Management.

Dr Palmer received his medical degree from Stanford University School of Medicine, CA; his law degree from Concord Law School, Kaplan University, Los Angeles, CA; his master’s degree in business administration from the University of California, Davis; and his master’s degree in public health from the University of California Los Angeles Fielding School of Public Health.

Jeffrey Patton, MD



Pamela Pelizzari, MPH

Principal and Healthcare Consultant, Milliman, Inc.

Pamela Pelizzari is Principal and Healthcare Consultant, Milliman, Inc., New York, NY, where she specializes in the development and management of episode-based payment methodologies. Prior to her current position, Ms Pelizzari was Adjunct Clinical Assistant Professor, New York University College of Global Public Health and Senior Technical Advisor and Health Insurance Specialist, Centers for Medicare & Medicaid Services, Baltimore, MD.

Ms Pelizzari’s expertise is in the analysis of healthcare claims and the development of episode-based payment definitions and benchmarking methodologies. She also has experience implementing prospective and retrospective payment methodologies, including developing gain-sharing methodologies, claims adjunction techniques, and quality monitoring programs.

Ms Pelizzari received her bachelor’s degree in applied mathematics from Brown University, Providence, RI, and her master’s degree of public health in healthcare policy and administration from Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Steve Peskin, MD



Pete Perron

President, Provider Solutions, McKesson Pharmaceutical Solutions and Services

Pete Perron is President of Provider Solutions, a business unit of the McKesson Corporation. In this role, he is responsible for overseeing day-to-day business operations and leading long-term strategic planning for the company’s specialty clinic provider business, value-added services business, and group purchasing organizations (GPOs), Onmark and Unity.

He brings tremendous leadership, credibility, and more than 28 years of healthcare experience in pharmaceutical and biotech sales, marketing, practice management, and business development. He joined McKesson 12 years ago and has held roles of increasing responsibility, most recently serving as Senior Vice President and General Manager, GPO Services.

Prior to this role, Mr Perron led a sales and account management team that partnered with outpatient clinics and specialty pharmacies to maximize practice and business efficiencies. Previous to that, he served as Vice President of Business Development in the McKesson Life Sciences organization. This team was responsible for identifying, developing, and selling solutions to pharmaceutical manufacturers that included informatics, provider engagement services, HEOR, clinical research, reimbursement services, patient support, and field commercialization assistance. Before joining McKesson, he spent 15 years in various sales, marketing, and leadership roles in the pharmaceutical and biotech space. He holds a master’s degree in interpersonal communication studies.

Denise Pierce

President, DK Pierce & Associates, Inc.

Denise Pierce has more than 35 years of leadership in biopharmaceutical and consulting industries, with significant depth in oncology. Denise and her company of 21 consultants, DK Pierce & Associates, have spent the past 20 years analyzing the evolution and trends of cancer care, supporting their vital role in strategic planning and ongoing patient access support for more than 30 oncology drugs/biologicals.

She has extensive working knowledge of oncology drug/biological access challenges in hospital inpatient, hospital outpatient, physician office, and home infusion settings of care. This includes the influence of health insurance coverage, coding, and payment dynamics within each setting.

DK Pierce & Associates, a certified Women’s Business Enterprise, has been recognized by the Govenor of Indiana for its business model, and has been a Best Places to Work In Indiana awardee for 3 years consecutively.

Dennis Purcell, MBA

Founder and Senior Advisor, Aisling Capital LLC

Dennis Purcell is Founder and Senior Advisor, Aisling Capital, LLC, New York, NY. Prior to his current position, Mr Purcell was Managing Director, Life Sciences Investment Banking Group, Chase H&Q, where he was directly involved with more than 200 completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries.

He has also served as a member of the Advisory Council, Harvard Medical School, and on the Board of Directors, Biotechnology Industry Association and the New York Biotechnology Association. Currently, he sits on the Board of Real Endpoints, Summus Global, Life Science Leader magazine’s Editorial Advisory Board, NY BIO Association, and is a member of the University of Delaware Investment Visiting Committee Member.

Mr Purcell received his bachelor’s degree in accounting from the University of Delaware, Newark, and received his master’s degree in business administration from Harvard Business School, Boston, MA.

Bruce Pyenson, FSA, MAAA



Cynthia Radford



Michael Reff, RPh, MBA

Executive Director, National Community Oncology Dispensing Association, Inc.

The National Community Oncology Dispensing Association (NCODA) is the first patient-centered organization dedicated to proactively helping to shape the value proposition for medically integrated oncology pharmacies. NCODA supports a membership of more than 1500 healthcare practitioners employed at over 400 practice settings. Mr Reff established The Patient Rx Center at Hematology/Oncology Associates of Central New York, a medically integrated oncology pharmacy service focused on positive patient experiences with oral oncolytics.

He serves on the Quality Oncology Practice Initiative Steering Committee of the American Society of Clinical Oncology. He also served on the Association of Community Cancer Centers’ Editorial Board, Government Affairs Committee, National Renal Cell Cancer Advisory Committee, and Dispensing Pharmacy Project Committee. He shares his passion for patients through delivering presentations and publishing articles addressing the importance of the continuity of care for oral oncolytics. He has extensive pharmaceutical industry experience, spanning many disciplines, including oncology research, corporate compliance, international supply chain, and biologics manufacturing.

Dan Renick, RPh



Christina Ritter, PhD



Mary Rivera, RN, AOCNS

Oncology Navigation Director, HCA South Atlantic Division

Mary Rivera is Oncology Navigation Director for the HCA South Atlantic Division. She is nationally certified as an Advanced Oncology Clinical Nurse Specialist by the Oncology Nursing Society. Ms Rivera started her career in the US Army Medical Corp and earned her MSN, graduating magna cum laude from Liberty University. Her tenure in oncology has spanned over several institutions and across multiple disciplines in oncology, including clinical research, inpatient, outpatient, and palliative care. She has a special interest in healthcare outcomes, informatics, clinical pathway development, and execution in the oncology patient environment. Her current role includes leading a team of oncology nurse navigators across the South Atlantic Division; bringing the Sarah Cannon Model of Navigation to this area.

Kent Rogers, MBA

Senior Vice President, Chief Formulary & Procurement Officer–Industry Relations, UnitedHealth Group

Kent Rogers is Senior Vice President, Chief Formulary & Procurement Officer–Industry Relations, OptumRx, Irvine, CA, where he is responsible for formulary and procurement contracting for all books of business on behalf of internal and external clients of UnitedHealth Group. Prior to his current position, he was Principal Consultant, Blue Fin Group, Budd Lake, NJ; Vice President, Managed Markets, Acorda Therapeutics, Ardsley, NY; and Director, Payer Strategy, US Managed Markets, Merck.

With more than 24 years of experience in the pharmaceutical industry, focusing primarily on payer, channel, and patient service strategies, Mr Rogers has vast experience in business development, health economics outcomes research, building and leading market access teams, developing and implementing payer access and channel strategies, and launching patient services programs.

Mr Rogers received his bachelor’s degree in business management and organizational change from Indiana University Bloomington, and his master’s degree in international business from Emory University Goizueta Business School, Atlanta, GA.

Darin Rubin

Partner & Managing Director, The Dedham Group

Darin Rubin has spent the past 20 years as a healthcare strategist focusing on the oncology and specialty therapeutics landscape drawing upon a knowledge base of biomedical sciences, epidemiology, managed markets, distribution models, and commercialization strategy. As a founding Partner and Managing Director of The Dedham Group, a leading oncology and specialty strategy consultancy, his work centers on advising management of pharmaceutical and biotechnology clients across a multitude of specialty therapeutic areas, technology platforms, and regional access ecosystems. At the forefront of local-level access strategies that engage emerging access influences (pathways/APMs, quality and value dynamics, digital therapeutics, molecular diagnostics, technology-based partnerships, etc), he has helped clients anticipate, target, and execute to address rapidly evolving customer and competitive needs. Mr Rubin is also a partner and co-founder of specialty therapeutics quality and value data provider, Pulse Digital. In academia, he earned his MPH in healthcare policy and management from Columbia University, an MBA in healthcare management from the University of Connecticut, postgraduate studies in molecular biology at Columbia University, and a bachelor’s degree in biochemistry from the University of Vermont.

Morrie Ruffin



Anil Rustgi, MD



Alex Santini



Don Sawyer



Eric Schultz

Co-Founder, Advisory Board, Ocean Genomics, Center for Machine Learning and Health, Carnegie Mellon University

Eric Schultz’s work at Ocean Genomics focuses on improving outcomes and total costs through case-appropriate data sources and analysis methods, including machine learning and other applications and approaches of artificial intelligence.

Ocean Genomics is a leading company in transcriptomics—the promising and fast developing frontier beyond genomics—and provides services for discovery and validation of transcriptomic biomarkers, as well as a comprehensive software pipeline with machine learning–based analysis modules that extract advanced gene expression features from bulk and single-cell RNA-seq. Prior to Ocean Genomics, Mr Schultz was Founding Chief Executive Officer of Cota, which built research-grade real-world evidence from the data and documents stored in electronic medical records and other clinical systems. Cota used the data and its proprietary patient classification system to power analyses to improve outcomes and costs. Prior to Cota, Mr Schultz founded QuantiaMD and ran it for 10 years as the largest massive online learning community for healthcare professionals.

His first 25 years were in enterprise and mobile technologies, building startups and serving in senior development roles at Lotus (1-2-3) and ADT Research Labs, and in executive roles at Microsoft and Qualcomm.

Lee Schwartzberg, MD, FACP

Medical Director, West Cancer Center

Lee Schwartzberg is Medical Director, West Cancer Center, Germantown, TN. In addition, he is Chief Medical Officer, OneOncology, Nashville, TN, and Professor of Medicine, The University of Tennessee Health Science Center, Memphis. Dr Schwartzberg specializes in the treatment of breast cancer, with a specific research focus on new therapeutic approaches, targeted therapy, and supportive care. He has published more than 240 articles in peer-reviewed journals, such as the Journal of Clinical Oncology, Lancet Oncology, and Annals of Oncology. Dr Schwartzberg was founding Editor-in-Chief of Community Oncology, and currently serves as the Editor-in-Chief of the Practice Update Oncology website. He serves on the editorial board of the Journal of Supportive Oncology and The ASCO Post and is a peer reviewer for many prominent medical journals. He currently serves on the NCCN Board of Directors and the NCCN Guidelines Steering Committee. He received his medical degree from New York Medical College, Valhalla, completed his residency at Cornell University/North Shore University Hospital, New York, NY, and his oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center, New York, NY.

Jeffrey Scott, MD

Chief Medical Officer, Integra Connect

Jeffrey Scott is the Chief Medical Officer of Integra Connect. He has an established track record of building market leading initiatives in community practice and group purchasing organizations (GPOs), bringing a multitude of innovative programs and organizations to the marketplace. He has helped lead and build one of the largest community oncology practices, Georgia Cancer; co-founded ION and associated specialty GPOs; co-founded P4 Healthcare, a multimedia oncology communication and education company; and most recently helped to transition the P4 business to its acquirer, Cardinal Health.

Dr Scott holds a medical degree from Wayne State University and a bachelor’s degree in microbiology and immunology from the University of Michigan.

John Simmons, PhD



Gregory Simon, JD

Past President, Biden Cancer Initiative

Gregory Simon is Past President, Biden Cancer Initiative, Washington, DC, the nonprofit organization that was built on the goals of the White House Cancer Moonshot program and Former Vice President Joe Biden and Dr Jill Biden’s commitment to double the rate of progress in preventing, detecting, diagnosing, treating, and surviving cancer. During his tenure, he helped launch more than 70 innovative private and public–private collaborations and numerous novel interagency initiatives that helped support the successful effort to secure $1.8 billion in new funding for the Cancer Moonshot program.

Prior to his role, Mr Simon was Executive Director, White House Cancer Task Force; Chief Executive Officer, Poliwogg, New York, NY; Senior Vice President, Worldwide Policy and Patient Engagement, Pfizer, New York; and Co-Founder and President, FasterCures, Washington, DC. He is also a survivor of chronic lymphocytic leukemia.

Mr Simon received his bachelor’s degree in history from the University of Arkansas, Fayetteville, and his law degree from the University of Washington School of Law, Seattle.

Surya Singh, MD

President and Owner, Singh Healthcare Advisors; Adjunct Instructor, Medicine, Harvard Medical School

Surya Singh is President and Owner, Singh Healthcare Advisors, Boston, MA, where he provides expertise and guidance on healthcare issues with a broad impact; and Adjunct Instructor, Medicine, Harvard Medical School, Boston. Prior to his current positions, he was Corporate Vice President and Chief Medical Officer, CVS Health Specialty, Providence, RI, where he was responsible for specialty client and clinical strategy, product innovation, analytics, clinical program management, and drug safety/pharmacovigilance.

Dr Singh has broad experience in overall business strategy and focuses on the adoption of novel therapies, acceleration of value-based reimbursement, predictive analytics, the use of artificial intelligence, and the clinical application of genomic sequencing. He has overseen multifaceted teams of clinicians and analysts; led several strategic initiatives, partnerships, and acquisitions in previous employments; and played key senior management roles during unprecedented business growth.

He obtained his bachelor’s degree in molecular biology from The University of Texas at Austin, and his medical degree from The Johns Hopkins University School of Medicine, Baltimore, MD.

Stan Skrzypczak, MS, MBA

Founder and Managing Partner, 5 Prime Life Science Consulting

Stan Skrzypczak is Founder and Managing Partner, 5 Prime Life Science Consulting, Pleasanton, CA, a company dedicated to guiding oncology corporate development, portfolio planning, global market access and reimbursement, health services research, basic science collaborations, and global deployment of precision medicine. His experience spans from therapeutic classes of oncology and immunology to commercializing drugs and biologics to tumor gene-expression profiling assays.

Prior to his current position, he was Vice President, Corporate Development and Reimbursement, Guardant Health, Redwood City, CA; Vice President, Business Development, Invitae, San Francisco, CA; Senior Director, Marketing & Global Strategy, Genomic Health, Redwood City; and Senior Product Manager, Immunology, Genentech, South San Francisco.

Mr Skrzypczak received his bachelor’s degree in biochemistry and molecular biology from the University of Rochester, NY; his master’s degree in microbiology and immunology from Wright State University, Dayton, OH; and his master’s of business administration degree in marketing from Xavier University, Cincinnati, OH.

Jayson Slotnik, JD, MPH



Cardinale Smith, MD, PhD

Associate Professor, Medicine, Hematology, and Medical Oncology, and Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Health System

Cardinale Smith is Associate Professor, Medicine, Hematology, and Medical Oncology, and Associate Professor, Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Health System, New York, NY. In addition, she is Director, Quality for Cancer Services, Mount Sinai Health System.

Dr Smith’s research focuses on physician–patient communication, evaluating treatment disparities in cancer care, determinants of cancer patients’ quality of care, characterizing barriers to optimal cancer and palliative care, and developing approaches to eliminating those barriers. She is currently pursuing research that will identify the cultural barriers and facilitators to utilization of palliative care among patients with cancer, in which she plans to use the data to develop a culturally competent palliative care intervention for minority patients with cancer. Due to her strong reputation as a researcher, clinical educator, and clinician, she has been selected as one of the 40 Inspiring Hospice and Palliative Medicine Leaders Under 40 by the American Academy of Hospice and Palliative Medicine.

Dr Smith obtained her bachelor’s degree in biology from Rutgers University, New Brunswick, NJ; her medical degree from Drexel University College of Medicine, Philadelphia, PA; and her doctorate degree from Icahn School of Medicine at Mount Sinai. She completed her internal medicine residency and fellowship at Mount Sinai School of Medicine, New York.

Ted Snelgrove, MBA



John Sprandio, MD, FACP

Chief Physician, Consultants in Medical Oncology and Hematology

John Sprandio is the founder and practice president of Consultants in Medical Oncology and Hematology (CMOH), an independent, community-based practice serving the greater Philadelphia region since 1988. A pioneer in both value-based care and electronic health record implementation, he assembled a team in 2003 to develop a software solution that would tackle the medical field’s “productivity paradox,” wherein physicians are expected to focus on data while drowning in an endless series of clicks and windows trying to access it. The result was IRIS™, a physician-centric user interface that not only solved this paradox, but drove consistency of care, reduced unnecessary costs for both patients and payers, and alleviated physician burnout and professional misery.

Dr Sprandio’s vision and innovations helped inform the development of the CMS Oncology Care Model, as well as many other alternate care and payment methodologies to help push the industry beyond the antiquated fee-for-service model.

In 2018, Dr Sprandio affiliated his practice with the US Oncology Network, which serves as a capital partner with the joint goal of aggregating like-minded independent practices to offer a strong value-based alternative to the large hospital systems in the region. Value-based care remains the core focus as he helps transform these practices and keeps them thriving in an increasingly competitive market.

Bethanie Stein, PharmD

Vice President, Strategic Contracting, Purchasing, and Analytics, Humana

Bethanie Stein is Vice President of Strategic Contracting, Purchasing, and Analytics at Humana. In this role, she leads the work relevant to the pharmaceutical supply chain, specifically pharmacy network contracting; trade relations; purchasing for Humana’s mail, specialty, and retail pharmacies; and analytics that support the pharmacy and PBM business. Her leadership of these combined organizations comes at a time of increased convergence in our relationships with pharmaceutical manufacturers, wholesalers, pharmacies, and payers, and analytics at the core of driving our strategy. Dr Stein joined Humana Pharmacy Solutions 10 years ago, starting as Pharmacy Resident, and has held several positions in the clinical and operational areas of the business.

Previously, she was Vice President of Trade Relations responsible for managing a multibillion-dollar pharmacy and value-based rebate program. She has also led formulary strategy, Medicare contracting strategy, and Humana’s pipeline and generic drug strategy in managing overall drug cost trends at Humana.

She received her doctorate degree in pharmacy at Duquesne University in Pittsburgh, PA. She went on to complete a 1-year managed care residency at Humana. She is a member of the Academy of Managed Care Pharmacy and the Pharmaceutical Care Management Association.

Charles Stevens, JD, MBA



Rob Stianchi

Director, US Marketing, Oncology Biosimilars, Merck Oncology

Robert Stianchi is Director, US Marketing, for Merck Oncology Biosimilars and is responsible for commercializing Merck’s oncology biosimilar portfolio of products in the United States.

He has worked in the biopharmaceutical industry for more than 15 years, where his career spans a wide breadth. This includes roles in basic research, biologics technology and engineering, pharmaceutical manufacturing, corporate strategy and Lean/Six Sigma, marketing research and analytics, global marketing, and US marketing.

While at Merck, he has helped launch or prepare for launch a portfolio of Merck’s biosimilars across the globe in oncology, as well as immunology and diabetes, for the past 10 years, and across 6 continents. Through his work, Mr Stianchi has become an expert in the dynamics of the biosimilars and off-patent biologic markets and has been invited to speak around the globe on the topic of biosimilars.

He has a bachelor’s degree in mechanical and aerospace engineering from Rutgers University and a master’s degree in business administration from Lehigh University. He also holds 10 medical device patents, published multiple scientific papers in several journals, is a certified Six Sigma Master Black Belt, and a Rutgers School of Engineering Distinguished Alumni Medal of Excellence winner (2014).

Arthur Taft, MBA

Managing Director, MedWorks Consulting, LLC

Arthur Taft is committed to the development of utilization management tools designed to improve medical and pharmaceutical quality and utilization. Effective oncology treatment and costs are an increasing concern and interest to his clients. Over his career, he served as Senior Operational Manager for SmithKline’s Health Management Services Chronic Disease Management efforts, including the consideration of how these programs can impact oncology care. Subsequently, he served as Vice President of Sales and Marketing at Accordant Health Services, an independent chronic disease management company at the time, whose programs included multiple conditions requiring specialty medications. He founded MedWorks Consulting in 2002, completing multiple projects for marketplace suppliers, including biotechs and pharmaceutical manufacturers as well as specialty pharmaceutical distributors. MedWorks has also supported commercial health benefit buyers from Fortune 50 to multiple group purchasing organizations.

He holds a bachelor’s degree and a master’s degree in operations research from Cornell University and a master’s of business administration degree in marketing/management from New York University.

Brad Tallamy

Senior Director, Government Affairs, AmerisourceBergen

Brad Tallamy is Senior Director of Government Affairs at AmerisourceBergen, where he is responsible for monitoring and analyzing emerging legislative and regulatory issues affecting AmerisourceBergen’s customers and the patients we serve. He routinely interacts with policymakers in Congress and regulatory authorities on issues such as drug pricing, reimbursement and controlled substance abuse, and strategizes on policy-forward approaches in healthcare’s evolving marketplace. Prior to his role at AmerisourceBergen, he was Vice President at Venn Strategies, where he established the Patient Access to Community Treatment coalition, comprised of more than 20 patient, caregiver, nursing, and provider organizations committed to ensuring patients have access to quality, affordable, community-based care. Mr Tallamy also served as Director of Federal Government Relations at the National Patient Advocate Foundation, where he championed patient access issues, specializing in legislative and regulatory analysis and coalition management. He also served as a data analyst at Columbia University Medical Center, where his work, in collaboration with internationally recognized researchers, was published in more than 20 peer-reviewed manuscripts. He earned his bachelor’s degree in political science at Loyola University in Maryland.

Michael Thompson



Barrett Thornhill, JD



Deborah Toppmeyer, MD



Harry Travis, BS Pharm, MBA

President/CEO, etectRx, Inc.

Harry Travis is an accomplished senior executive with more than 25 years of experience in all aspects of pharmaceutical distribution channel management. Currently, he is President and CEO of etectRx, Inc. etectRx has developed an innovative digital pill system that incorporates a tiny ingestible sensor into a capsule, which transmits a signal to a wearable reader and then to a smartphone-based app and secure cloud-based server to reliably and safely indicate when a patient has taken their medicine.

He has held senior leadership positions with Baxter Healthcare, Cardinal Health, Accredo/Medco, and Aetna. Most recently, he was Vice President of Aetna’s Specialty and Home-Delivery Pharmacy Business. He holds a bachelor’s degree in pharmacy from the University of Pittsburgh School of Pharmacy and a master’s degree from the Darden School at the University of Virginia.

Michael Valenta



Amy Valley, PharmD, BCOP



Joe Vandigo, MBA, PhD



F. Randy Vogenberg, PhD

Principal, Institute for Integrated Healthcare (IIH)

F. Randy Vogenberg is Principal of the Institute for Integrated Healthcare (IIH), Greenville, SC (formerly in Providence, RI, and Boston, MA). His prior posts include Senior Vice President, Aon Consulting North America.

He currently serves as Board Chair for the Employer-Provider Interface Council of the Hospital Quality Foundation; Co-Leader, National Employer Biologics & Specialty Initiative with the Midwest Business Group on Health; and Fellow of the Foundation for HealthSmart Consumers.

His work for self-funded employers includes innovative contracting, legal compliance, and holistic care cost management to drive high-performing plans. His commercial/employer benefits and care delivery issues expertise has produced several books, papers, and presentations in peer-reviewed journals and venues. Dr Vogenberg has also published and presented widely on clinical effectiveness; real-world economic outcomes; law; policy and regulation; organizational and patient behavior; continuum of care concepts; and insurance innovation. He continues to be the subject of articles and interviews about market changes or innovation.

A pharmacist by education from the University of Rhode Island, Dr Vogenberg continued his training through a residency at Brigham & Women’s Hospital/Harvard Medical School, and education with a doctorate in healthcare management from Century University.

Clorinda Walley

President, Good Days

Clorinda Walley leads the Good Days charity with more than 20 years of experience in the healthcare industry and over 8 years in strategic philanthropy. She effectively oversees the strategic and operational responsibility for the staff and programs for Good Days, as well as the expansion and execution of its mission. With in-depth knowledge of the organization’s core programs, operations, and business plans, she ensures the organization’s programmatic excellence. With her proven expertise, Ms Walley has continuously ensured consistent quality of finance and administration, procurement of donations, internal and external communications, and development of all patient care initiatives.

Jennifer Walsh

Director, Public Affairs, Foley & Lardner LLP

Jennifer Walsh is Public Affairs Director with Foley & Lardner LLP. She has extensive experience in government affairs, including a lengthy career as a senior staffer in the US Congress and the California legislature, and as a vice president for Federal Government Affairs at a top 20 Fortune 500 healthcare company. Ms Walsh has effectively advanced key issues before the US Senate, House of Representatives, and the Administration. She is a member of the firm’s Government & Public Policy Practice.

Prior to joining Foley, Ms Walsh served as vice president for federal government affairs at a leading multinational healthcare company, where she developed and executed strategies to impact policy objectives and increase the company’s visibility among opinion leaders. Ms Walsh collaborated with colleagues across the healthcare industry, including third parties and trade associations to ensure effective execution and success of the company’s priorities.

Ms Walsh served 9 years as Chief of Staff to former Congressman Dennis Cardoza, 18th District of California. She was chief advisor and principal strategist on all legislative and political activity and served as primary liaison with the Bush and Obama administrations, members of Congress, the Congressional Hispanic Caucus, and the California Democratic Delegation. She also served as finance director for the Cardoza for Congress campaign, where she developed and managed a $2-million fundraising effort.

Previously, she served as a chief of staff in the California State legislature as well as a congressional field representative, deputy campaign manager, and House Democratic Caucus program director to former Congressman Vic Fazio, 3rd Congressional District of California.

Ms Walsh graduated from the University of Maryland with a bachelor’s degree in government and politics, minoring in Spanish.

Adria Warren, JD



David Waterhouse, MD, MPH

Chief, Clinical Research Department, Oncology/Hematology Care

David Waterhouse is Chief, Clinical Research Department, Oncology/Hematology Care, Cincinnati, OH, and a member of the Clinical Research Committee for the American Society of Clinical Oncology. Prior to his current role, Dr Waterhouse was Associate Professor, Medical Oncology, University of Cincinnati College of Medicine, and a member of the Grant Review Committee at the Susan Komen Foundation in Ohio.

For more than 20 years, Dr Waterhouse has dedicated his career to advancing cancer research and improving patient access to treatments. His research specialties include lung cancer, urologic cancer, and clinical trials research, and the effect of cancer research on patients.

He received his bachelor’s degree from the College of the Holy Cross, Worcester, MA; his medical degree from the University of Massachusetts Medical School, Worcester; and his master’s degree in public health from the University of Michigan School of Public Health, Ann Arbor.

Susan Weidner, MBA

SVP, IntrinsiQ AmerisoureBergen

Susan Weidner is currently Senior Vice President of IntrinsiQ Specialty Solutions, part of AmerisourceBergen. She is responsible for IntrinsiQ Analytics, AdvanceIQ Network, a community-based provider research network, and precision medicine strategy. She has more than 20 years of healthcare experience, including the pharmaceutical industry. As an executive at pharmaceutical, healthcare consulting, and precision medicine companies, she has led the design, development, and implementation of innovative healthcare solutions, including those driven by healthcare informatics. Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers, and providers in demonstrating the value of their products and/or their organizations.

She has a master’s degree in biostatistics from the Ohio State University and a bachelor’s degree in mathematics and statistics from Eastern Kentucky University.

David Wierz



Lalan Wilfong, MD

Chairman, Pathways Taskforce, US Oncology

Lalan Wilfong is a medical oncologist/hematologist with Texas Oncology, PA. In addition to patient care, he serves as the Executive Vice President for Quality Programs and Value-Based Care for Texas Oncology and as a physician liaison for value-based care for McKesson Specialty Health.

His current research interest focuses on aligning quality patient care and value in a community- based setting. He is the physician leader for the Oncology Care Model for Texas Oncology. Other areas of focus include improving patient/physician communications, enhancing end-of-life care, integrating pathways into clinical practice, and improving patient satisfaction.

He co-chairs the Value-Based Physician Champion Task Force for The US Oncology Network. He also serves on the US Oncology Pharmacy & Therapeutics Committee as well as chairs the Pathways Task Force. He also volunteers on the American Society of Clinical Oncology (ASCO) Quality Measures Task Force and the ASCO Guidelines Committee. He has been honored to receive various teaching and community service awards.

He earned his medical degree from the University of Texas Southwestern Medical School, Dallas, in 1997. He completed his internship and residency in internal medicine at the University of Texas Southwestern Medical School, Dallas, in 2000. In 2003, he completed a fellowship at the University of Texas Southwestern Medical School in hematology and medical oncology. He earned a bachelor’s degree in mathematics at Texas Tech University in Lubbock in 1993.

William Winkenwerder, MD

Chairman, Winkenwerder Strategies, LLC

William Winkenwerder, Jr, is Chairman, CitiusTech, Princeton, NJ, and Chairman and Chief Executive Officer, Winkenwerder Strategies, Locust Valley, NY. He is one of the most influential and recognized leaders in American healthcare, with experience in medical care, healthcare finance, and health insurance operations. He is also an expert on federal health policy and programs, and new technologies, such as electronic health records.

Previously, Dr Winkenwerder was Chief Executive Officer, Highmark Health, Pittsburgh, PA, where he led a transformation to create the third largest integrated healthcare delivery and financing network in the nation. Highmark Health operates Blue Cross Blue Shield plans in multiple states, as well as Allegheny Health Network comprised of 7 hospitals and more than 2500 affiliated physicians. He has been an advocate for preventive healthcare, evidence-based medicine, Internet technology–based solutions, and consumer engagement.

He received his bachelor’s degree in pre-medicine from Davidson College, Davidson, NC, and his master’s degree in business administration from The Wharton School, Philadelphia, PA. He received his medical degree from the University of North Carolina at Chapel Hill School of Medicine, and completed his residency at North Carolina Memorial Hospital, Chapel Hill.

William Yoon, PharmD, MBA



Danielle Ziernicki, PharmD

Head, Medical & Regulatory Affairs, The Dedham Group

Danielle Ziernicki is Head of Medical and Regulatory Affairs for The Dedham Group, New York, NY, where she leads strategies for the company and its various pharmaceutical clients across multiple therapeutic areas for pipeline and marketed products by delivering focused analyses to enhance product market access. Previously, she was Director, Health Care Quality, Johnson & Johnson and Janssen Oncology and Immunology, Horsham, PA, where she delivered oncology and immunology-focused value-based care, healthcare quality, and payment model analyses to enhance marketing strategies and access.

Dr Ziernicki has more than 19 years of pharmaceutical business experience in the areas of global regulatory intelligence and policy, drug development, medical affairs/medical information, US market access, healthcare policy, quality and value-based care, marketing support, and academia.

She obtained her bachelor’s degree in pharmacy (cum laude) at the University of the Sciences in Philadelphia, PA, where she also obtained her doctorate in pharmacy (cum laude). She also holds a graduate certificate in health policy from Thomas Jefferson University School of Public Health, Philadelphia, PA.

Burt Zweigenhaft, BS

Managing Partner, Upstream Partners

Burt Zweigenhaft is Managing Partner, Upstream Partners, New York, NY, where his guidance has supported several key drug launch market strategies with industry leaders, such as Gilead, Janssen, Pfizer, Genentech, and emerging biotechnology incubators. He also serves as Senior Advisor to the shareholder group, Cancer Treatment Centers of America, and is Past President of the National Association of Specialty Pharmacy, representing the industry on national policy, specialty pharmacy education, and government relations based in Washington, DC.

Prior to his current position, Mr Zweigenhaft was the Founder and held offices as the Chief Executive Officer and Vice Chairman of Onco360 Oncology Pharmacy, South Plainfield, NJ. The Onco360 model provides the full continuum of oncology pharmacy service solutions to more than 3000 community- and hospital-based hematologists, oncologists, and cancer centers of excellence in coordination with managed care providers insuring more than 45 million people. Mr Zweigenhaft’s vision and leadership developed the industry standards for the best practice oncology pharmacy model by incorporating the strengths of board-certified oncology pharmacists and oncology patient advocates to support the prospective and concurrent patient-centered oncology medical home model.

Mr Zweigenhaft obtained his bachelor’s degree in economics and business management from the State University of New York at Buffalo School of Management, where he also serves on the Dean’s Advisory Committee and remains active with the University of Buffalo’s schools of pharmacy and medicine, including the Center of Excellence for Bioinformatics and Health Sciences.

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: